Tirzepatide
LY3298176 · Mounjaro · Zepbound
FDA-APPROVED · GIP/GLP-1 DUAL INCRETIN AGONIST
▓ 451 indexed citations across PubMed (225), ClinicalTrials.gov (169), EuropePMC (57).
Citation breakdown by evidence tier
← weaker evidence · stronger evidence →
Tap any tier to jump to that section of the bibliography.
Background
Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes and for weight loss. Tirzepatide is administered via subcutaneous injections. It is sold in several countries under the brand name Mounjaro for diabetes treatment. In the United States it is sold with the trade name Zepbound for weight loss and treatment of obstructive sleep apnea.
Mechanism of action
Researched effects
Reported efficacy (trial readout)
-
Weight Loss 22%
~22% (SURMOUNT-1, 72wk)
High confidencen=3762025 -
Hba1c Reduction 2.6%
Lancet (Phase 3, 52wk, n=338)
High confidencen=338Phase 32021 -
Mash Resolution 62%
NEJM (Phase 2, 52wk, n=48)
High confidencen=48Phase 22024
Trial-efficacy data current as of November 16, 2026.
Live evidence
FDA label safety
WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )]. ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC…
4 CONTRAINDICATIONS ZEPBOUND is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.2 )] . Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 ( 4 ) Known serious hypersensitivity to…
Active clinical trials 180
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial
- Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension
Reported adverse events 3,776
Events spontaneously reported to the FDA FAERS database since 2015. A report does not establish that the drug caused the event, and counts do not reflect how often it occurs. Discuss any concern with a clinician.
FDA FAERS →Recent literature
- Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes.
- Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.
- Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.
Live signals refreshed daily. Current as of November 19, 2026.
Dosing reported in literature
2.5 mg SC weekly (Mounjaro/Zepbound label starting dose, escalate by 2.5 mg monthly to label max 15 mg weekly per SURMOUNT escalation schedule) 123
→ FDA Mounjaro/Zepbound prescribing information (starting dose); SURMOUNT-1 escalation schedule (PMID 35658024)
Known concerns
Top-ranked picks
10 pre-curated authoritative sources, ranked by journal tier and study weight.
- Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
- Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
- Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis.
- Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.
- Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
- Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.
- Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.
- Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.
Full citation library
Year distribution
No references match — clear filters.
Meta-Analyses
42-
1.
We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus. We searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in…
-
2.
Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires evaluation. This pre-specified cardiovascular meta-analysis included all seven randomized controlled trials with a duration of at least 26 weeks from the tirzepatide T2D clinical development program, SURPASS. The pre-specified primary objective of this meta-analysis was the comparison of the tim…
-
3.
Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for marketing approval. Individual trials have assessed the clinical profile of tirzepatide vs different comparators. We conducted a systematic review and meta-analysis to assess the efficacy and safety of tirzepatide for type 2 diabetes. We searched PubMed, Embase, Cochrane and ClinicalTrials.gov up until 27 October 2021 for randomised control…
-
4.
Recent studies suggest that tirzepatide, a dual glucose-dependent insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has significant weight loss effects. This systematic review and meta-analysis aims to assess the efficacy and safety of tirzepatide for weight loss in patients with overweight or obesity. Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide's weight loss efficacy for these patients. A single ar…
-
5.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown significant metabolic benefits and weight reduction, but its anti-inflammatory effects have been less studied. This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6). A random-effects model was used. Seven randomized clinic…
-
6.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as an efficacious treatment for type 2 diabetes mellitus (T2DM) and have demonstrated substantial weight loss effects. This systematic review compares two prevalent GLP-1RAs, tirzepatide and semaglutide, with their weight loss effects and rates of adverse events (AEs). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), a systematic search was performed in PubMed, Embase and Cochrane Library…
-
7.
Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.
To perform a meta-analysis to quantify the effect of tirzepatide on blood pressure and lipids. PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating the effects of tirzepatide on either blood pressure or lipid profiles were included. Seven randomized controlled trials have investigated the effects of tirzepatide on blood pressure and lipid profiles. Regardless of the dose administered, tirzepatide resulte…
-
8.
Obesity is a complex chronic condition linked to various comorbidities, such as hypertension, diabetes, and dyslipidaemia, with a significant global burden. Standard treatments, such as diet, exercise and behavioural changes, often have limited effects and poor compliance. Pharmacological options, including glucagon-like peptide receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP) dual agonists, show promise for individuals with obesity. This is one of three review…
-
9.
Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide. RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases. The primary outcome was the overall risk of any cancer, and secondary outcomes were the risks of spec…
- 10.
- 11.
-
12.
This systematic review and meta-analysis compared the weight loss efficacy of tirzepatide versus semaglutide in overweight and obese adults through direct comparative studies. We systematically searched PubMed, Excerpta Medica database (EMBASE), Web of Science, and Cochrane Library databases from inception to April 25, 2025, identifying studies that directly compared tirzepatide and semaglutide for weight management. Inclusion criteria encompassed randomized controlled trials and observational s…
-
13.
Type 2 diabetes (T2D), as well as obesity, are risk factors for chronic kidney disease (CKD) and end-stage renal disease. The renal impacts of glucose-lowering and weight-lowering drugs and their potential benefits in preventing CKD often guide clinicians in choosing them appropriately. Only limited data based on randomized controlled trials (RCTs) is currently available on the renal effects and safety profile of tirzepatide. To explore the renal benefits and safety of tirzepatide RCTs involving…
-
14.
The aim of the study was to compare the effectiveness of tirzepatide versus semaglutide in producing weight loss. A systematic search was conducted in databases PubMed, Scopus, and Web of Science on January 22, 2025, using search terms ("tirzepatide," "semaglutide," and "weight loss") and their alternatives, which yielded 751 studies in total. After deduplication, title/abstract and full text screening was conducted, and studies were assessed based on the eligibility criteria. After extracting t…
-
15.
Despite therapeutic benefits, discontinuation of tirzepatide is common in randomized controlled trials (RCTs) due to adverse events (AEs) and other causes. No previous systematic reviews have explored the reasons for discontinuing tirzepatide in the RCTs. To explore the reasons for permanent discontinuation of tirzepatide Relevant RCTs were systematically searched using related terms through multiple databases such as MEDLINE ( Seventeen RCTs ( The discontinuation risk is not higher in tirzepati…
-
16.
Endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) regulate islet cell function. GLP-1 receptor agonists (GLP-1RAs) have been associated with an elevated risk of acute pancreatitis. Data on the pancreatic safety of tirzepatide (a dual GLP-1 and GIP agonist) and its effects on islet cell function in randomized controlled trials (RCTs) are scarce. Moreover, no meta-analysis has comprehensively examined such effects of tirzepatide. Electronic databases…
-
17.
<b>Background:</b> Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates substantial glycemic and weight benefits versus GLP-1 receptor agonists in indirect comparisons, but direct comparative safety evidence versus dulaglutide remains limited. We evaluated comparative safety (primary outcome: overall adverse events) and efficacy. <b>Methods:</b> Following PRISMA 2020 (prospectively registered: PROSPERO CRD420251276594), we searched MEDLINE, Embase, Scopus, and CENTRAL (inception-31 Decem…
-
18.
Spinal fusion is a widely performed surgical procedure for treating various spinal disorders, with lumbar fusion showing remarkably rapid growth worldwide. Despite positive outcomes after the procedure, it carries significant complications, most notably pseudarthrosis. Compromised blood supply is a key factor disrupting normal bone fusion, making optimal vascularization crucial for successful outcomes. Glucagon-like peptide-1 (GLP-1) receptor agonists, primarily used for diabetes management, dem…
-
19.
Metabolic bariatric surgery is a highly effective weight-loss intervention. Nevertheless, a non-negligible proportion of patients experience a suboptimal clinical response, which may present as insufficient weight loss or weight regain after an initial loss. In these cases, weight management pharmacotherapy can be considered. We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in…
-
20.
Tirzepatide is a dual agonist for glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, with proven efficacy in weight loss and improvement in cardiovascular outcomes. However, the effects of tirzepatide on the incidence of atrial fibrillation in patients with overweight or obesity remain unclear. PubMed, Embase, and Cochrane Library were searched for randomized controlled trials comparing tirzepatide versus placebo for individuals with overweight or obesity. Odds r…
-
21.
This network meta-analysis addresses the limited dose-specific comparative evidence by evaluating different doses of tirzepatide (TZP) versus dulaglutide (DULA) for glycemic control, weight loss, and safety in type 2 diabetes mellitus (T2DM). Following PRISMA and Cochrane guidance, we searched major databases for RCTs comparing TZP and DULA in adults with T2DM. Efficacy outcomes included body weight change (Weeks 12 and 16) and mean HbA1c change (Weeks 12 and 24). Safety outcomes included mortal…
-
22.
Semaglutide and tirzepatide produce substantial weight loss during treatment, but the trajectory of weight regain after discontinuation remains uncertain. To estimate post-discontinuation weight-regain trajectories and explore predictors of faster regain. We used published timepoint-level aggregate data from studies evaluating weight change after discontinuation of semaglutide or tirzepatide to perform a Bayesian hierarchical longitudinal re-analysis. The model estimated weight loss at cessation…
-
23.
This systematic review and meta-analysis aimed to compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity. We included randomised controlled trials and observational studies comparing tirzepatide and semaglutide with ≥ 24 weeks of follow-up. The primary outcome was percentage weight change from baseline. Secondary outcomes included absolute weight change, weight-loss thresholds, HbA1c and safety outcomes. Ten studies including 4…
-
24.
There are less comparisons among once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs),which is not conducive to refined clinical treatment. We searched in Pubmed, Embase, and Cochrane Central Register of Controlled Trials from database creation date to June 1, 2024. The primary glycemic efficacy was changes from baseline to endpoint for HbA1c. We performed Bayesian network meta-analysis calculating mean differences (MDs) for continuous outcomes and odds ratios (OR) for dichotomous ou…
-
25.
Tirzepatide and semaglutide are widely used for type 2 diabetes mellitus (T2DM) and obesity. However, the blood pressure-related adverse event profiles associated with tirzepatide and semaglutide remain unclear. This study systematically evaluated hypertension- and hypotension-related treatment-emergent adverse events (TEAEs) that occurred when using tirzepatide and semaglutide for the treatment of T2DM or obesity. A comprehensive search was performed in PubMed, Scopus, Web of Science, Embase, C…
-
26.
The rapid rise in overweight and obesity worldwide underscores the need for comparative evidence on long-term pharmacotherapy. The recent introduction of a 7.2 mg maintenance dose of semaglutide warrants particular attention. We assessed the efficacy and safety of glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists-liraglutide, semaglutide, and tirzepatide-focusing on the incremental value of semaglutide 7.2 mg. We conducted a systematic…
-
27.
To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all-cause mortality. We performed a pairwise and network meta-analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active comparator, in which MACE and deaths were adjudicated. We included 93 studies. In pairwise meta-analyses, versus all comparators, GLP-1 receptor agonists (GLP1RA), SGL…
-
28.
Glucagon-like peptide-1 (GLP-1) receptor agonists, including the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide, produce substantial weight loss, yet their effect on objectively measured dietary intake has not been quantitatively synthesized. We assessed their impact on ad libitum lunch energy intake. We searched six databases through March 31, 2026, for studies reporting quantitative dietary outcomes in adults receiving a GLP-1 or dual GIP/GLP-1 r…
-
29.
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial weight loss in adults with obesity. Given ethnic differences in obesity phenotype and cardiometabolic risk, this systematic review and meta-analysis compared tirzepatide's efficacy and safety between Asian and non-Asian adults without diabetes. This PROSPERO-registered review (CRD420261361351) searched PubMed, Scopus, Web of Science and ClinicalTrials.gov through 15 March 2026. Phase 3 SURMOUNT randomised, placebo-controlled tr…
-
30.
Semaglutide and tirzepatide are widely used drugs in the treatment of metabolic diseases based on incretin-based therapy. However, evidence on coronary artery disease (CAD)-related outcomes has largely been derived from separate randomized trials with different control groups, and focused synthesis across CAD phenotypes remains limited. This study aimed to evaluate CAD-related outcomes reported in randomized controlled trials (RCTs) of semaglutide and tirzepatide in adults with type 2 diabetes (…
-
31.
To assess the effect of tirzepatide, a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonist, on cardiovascular outcomes and mortality in subjects with overweight/obesity, or type 2 diabetes mellitus (T2DM). We searched MEDLINE, Embase and CENTRAL up to January 14, 2026, selecting randomized controlled trials studying tirzepatide in adults with T2DM or overweight/obesity with a minimum follow-up of 24 weeks. We independently extracted data and assessed risk of bias and…
-
32.
To provide an up-to-date evidence summary about the comparative benefits and harms of drugs for adults with overweight or obesity to inform decision making for policymakers, payers, clinicians, and patients. Systematic review and network meta-analysis of 24 outcomes using frequentist random effects models and bayesian dose-response models, the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach, and the Cochrane Risk of Bias 2 tool. Medline, Embase, and Cochrane L…
-
33.
To compare cardiovascular outcomes associated with tirzepatide versus glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in adults with overweight or obesity. PubMed/MEDLINE, Embase and the Cochrane Central Register of Controlled Trials were searched through 30 March 2026. The study was registered in PROSPERO (CRD420261354941). Randomized and observational studies comparing tirzepatide with GLP-1 receptor agonists and reporting cardiovascular outcomes were included. Data were extracted on stu…
-
34.
Long-term weight management drugs have the potential to reduce body weight and blood pressure in obese or overweight individuals. Being overweight or obese is often associated with hypertension, which is linked to an increased risk of cardiovascular mortality and morbidity. The effects of weight-reducing drugs on patient-relevant outcomes, especially in people with hypertension, are currently unclear. This review is the fourth update of one first published in July 2009. Primary objective To asse…
-
35.
Antidiabetic drugs differ in their effects on body composition, which may influence metabolic and functional outcomes. This systematic review and network meta-analysis aimed to quantify and compare effects of major antidiabetic drugs on key body composition parameters. PubMed, Web of Science and Scopus were searched from inception to March 2025 for randomized controlled trials. Network meta-analyses used a frequentist random-effects framework to estimate mean differences (MDs) and 95% confidence…
-
36.
Overweight and obesity are closely linked to diseases such as type 2 diabetes, coronary heart disease, and stroke and have been shown to increase mortality risk. To conduct a living systematic review of pharmacologic treatments for weight management in overweight or obesity in adults. MEDLINE and Cochrane Central Register of Controlled Trials until October 2025. Randomized controlled trials that compared pharmacologic treatments for weight management (dulaglutide, exenatide, liraglutide, lixisen…
-
37.
Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk. Tirzepatide, semaglutide, cagrilintide and their combination (CagriSema) have demonstrated efficacy in clinical trials; however, no direct head-to-head studies have compared all advanced ant…
-
38.
Metabolism-associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases worldwide. In recent years, although a network meta-analysis evaluated the efficacy of different drugs for patients with MASLD, it did not provide the specific dosage of the drugs and could not be accurately applied to the specific population for MASLD and fibrosis stages F1-F3, which greatly affected the extensibility and accuracy of the evidence. Therefore, this study aimed to evaluate the…
-
39.
Whether tirzepatide's kidney effects extend from albuminuria lowering to filtration preservation and clinical outcomes remains uncertain. We searched PubMed, Embase, and the Cochrane Library through August 2026 and mapped randomized reports to independent parent trials. Ten parent trials provided kidney data; eight informed each principal synthesis. Versus insulin, tirzepatide reduced urinary albumin-to-creatinine ratio by 27.0% (95% CI, 16.0%-36.6%; I2 = 37.8%; moderate certainty), whereas plac…
-
40.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiometabolic outcomes, but their isolated effects on human bone remodeling remain uncertain because prior syntheses pooled heterogeneous study designs and active antidiabetic comparators. This systematic review and meta-analysis quantified the effects of GLP-1RAs versus placebo on densitometric, biochemical, and inflammatory markers of bone metabolism in randomized controlled trials (RCTs). Scopus, Web of Science, Embase, and PubMed…
-
41.
Arrhythmias are often associated with comorbidities such as diabetes and obesity, which significantly influence their onset and progression. In this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have garnered attention for their potential benefits, with emerging evidence indicating that GLP-1 receptor activation may offer antiarrhythmic effects. This study aimed to evaluate the impact of all GLP-1 RAs and coagonists on the incidence of new-onset arrhythmias, particularly atrial…
-
42.
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated clinical benefits in heart failure with preserved ejection fraction (HFpEF) and obesity. However, its effects on cardiorenal biomarkers and functional capacity have not been comprehensively synthesized. We hypothesized that tirzepatide produces significant reductions in cardiorenal biomarkers and improvements in functional capacity compared to placebo or s…
Systematic Reviews
12-
43.
Tirzepatide is a new molecule capable of controlling glucose blood levels by combining the dual agonism of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. GIP and GLP1 are incretin hormones: they are released in the intestine in response to nutrient intake and stimulate pancreatic beta cell activity secreting insulin. GIP and GLP1 also have other metabolic functions. GLP1, in particular, reduces food intake and delays gastric emptying. Moreover,…
-
44.
Tirzepatide has become a treatment option for weight management, with increasing interest in its effects on skeletal muscle. This systematic review evaluated the impact of tirzepatide on skeletal muscle mass and lean body composition in adults. A structured search of four major databases was conducted up to June 26, 2025, following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. The included studies were randomized clinical trials that assessed skeletal mu…
-
45.
<h4>Background</h4>Glucagon-like peptide-1 (GLP-1) receptor agonists have gained popularity after clinical trials demonstrated their weight-loss potential. The term "Ozempic® face" has been coined to describe the exaggerated volume loss from semaglutide therapy, resulting in advanced facial aging.<h4>Objectives</h4>The authors of this study aim to review plastic surgery publications discussing GLP-1 receptor agonists and characterize the public's perception of the effect of these medications on…
-
46.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective antidiabetic and anti-obesity agents. Recent development and optimisation of these agents includes biased agonism (selective activation of a downstream signalling pathway) of the GLP-1 receptor, which has demonstrated greater weight-lowering effects and improved insulin response in treated persons relative to other GLP-1 RAs. We aim to synthesise current literature reporting on the effects of biased GLP-1 RAs and compare…
-
47.
<b>Background:</b> Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, which presents with painful nodules, abscesses and sinus tracts. Patients suffer from pain, drainage and worsening of mental health and quality of life. Treatment is often difficult. HS is typically associated with obesity and metabolic syndrome; thus, antidiabetics, especially GLP-1 agonists, present a potential therapy option. The aim of this review was to analyze the effects of GLP-1 agonists on patients…
-
48.
ObjectiveTo evaluate glucagon-like peptide-1 receptor agonist (GLP-1 RA)-specific associations with hair loss, characterize reported alopecia subtypes and discuss potential underlying mechanisms.MethodsA systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384). Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.ResultsOf 133…
-
49.
<h4>Background</h4>Overweight and obesity are increasingly common in adults with type 1 diabetes (T1D), contributing to insulin resistance, higher insulin requirements, and greater cardiometabolic burden. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has shown major metabolic benefits in type 2 diabetes and obesity, but its role in T1D remains unclear. This systematic review evaluated tirzepatide as adjunctive therapy to insulin in…
-
50.
Incretin-based therapies, including glucagon like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are increasingly prescribed for obesity, leading to greater recognition of associated dermatological adverse events (AEs). We aimed to characterize the spectrum, frequency, and clinical characteristics of cutaneous AEs reported with semaglutide, liraglutide and tirzepatide, focusing on these agents because of their established use in both wei…
-
51.
To summarise existing evidence regarding the values, preferences, and perceived treatment burden of adults with type 2 diabetes when considering initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), finerenone, or tirzepatide. Systematic review. Medline, Embase, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched from database inception to 7 January 2025 (updating a previous systematic review…
- 52.
-
53.
Doxorubicin (DOX)-induced cardiotoxicity remains a major limitation of cancer therapy. Incretin-based therapies are established cardiometabolic agents with pleiotropic cardiovascular effects; however, their potential role in mitigating DOX-related cardiac injury has not been systematically synthesized. We conducted a PRISMA 2020-compliant systematic review to evaluate the effects of incretin-based therapies on DOX-induced cardiotoxicity, with a focus on functional, structural, biomarker, and mec…
-
54.
Suboptimal weight outcomes, including recurrent weight gain (RWG) and insufficient weight loss (IWL), remain important clinical challenges after metabolic bariatric surgery (MBS). Although tirzepatide has demonstrated substantial weight loss in nonsurgical populations, its role after MBS remains uncertain. This systematic review evaluated the clinical outcomes of tirzepatide initiated after MBS in adults. We conducted a systematic review following PRISMA 2020 guidance. PubMed (MEDLINE), Embase,…
Randomised Controlled Trials
52-
55.
The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown. To assess the effect of tirzepatide, with diet and physical activity, on the maintenance of weight reduction. This phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries with a 36-week, open-label tirzepatide lead-in period followed by a 52-week, double-blind, placebo-controlled period included adults with a body mass index greater than or equal to 30 or greater than…
-
56.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1…
-
57.
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis is unclear. We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MAS…
-
58.
Despite advancements in care, many people with type 2 diabetes do not meet treatment goals; thus, development of new therapies is needed. We aimed to assess efficacy, safety, and tolerability of novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist tirzepatide monotherapy versus placebo in people with type 2 diabetes inadequately controlled by diet and exercise alone. We did a 40-week, double-blind, randomised, placebo-controlled, phase 3 trial (SURPASS-1), at 52 med…
-
59.
The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment of type 2 diabetes have not been described. To assess the efficacy and safety of tirzepatide added to insulin glargine in patients with type 2 diabetes with inadequate glycemic control. Randomized phase 3 clinical trial conducted at 45 medical research centers and hospitals in 8 countries (enrollment from August 30, 2019, t…
-
60.
A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM). LY3298176 is a fatty acid modified peptide with dual GIP and GLP-1 receptor agonist activity designed for once-weekly subcutaneous administration. LY3298176 was characterised in vitro, using signaling and functional assays in cell lines expressing recombinant or end…
-
61.
To evaluate the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide. In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28. Tirzepatide treatment demonstrated significant reductions in bod…
-
62.
Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.
Tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, promoted significant body weight reduction in the phase 3 clinical trials. We conducted a preclinical study and a phase 1 clinical trial (NCT04081337) to understand potential mechanisms mediating tirzepatide-induced weight loss in mice and people with obesity. In calorie-restricted, obese mice, chronic treatment with tirzepatide reduced the drop in energy expenditure that occurred in vehicle…
-
63.
As the disease progresses, many patients with type 2 diabetes have difficulty in reaching treatment goals. We aimed to assess the efficacy and safety of tirzepatide, a novel GIP and GLP-1 receptor agonist, compared with dulaglutide in Japanese patients with type 2 diabetes. This multicentre, randomised, double-blind, parallel, active-controlled, phase 3 trial was conducted in 46 medical research centres and hospitals in Japan. Adults aged 20 years or older with type 2 diabetes who had discontinu…
-
64.
Data on tirzepatide in Asian patients with obesity are limited. This study aimed to gain a better understanding of tirzepatide for treatment of Japanese patients with obesity disease (BMI ≥25 kg/m This was a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial of the efficacy and safety of tirzepatide as an adjunct to lifestyle modifications. Japanese adults with obesity disease (BMI ≥27 kg/m Between May 10, 2021, and June 24, 2023, 413 participants were screened, and 267 wer…
-
65.
Obesity is a known risk factor for heart failure with preserved ejection fraction (HFpEF) and is considered a distinct phenotype with more concentric remodeling. Epicardial adipose tissue (EAT) is also increased in obesity-related HFpEF and is associated with adverse events. The cardiac magnetic resonance (CMR) substudy of the SUMMIT trial aimed to examine the effects of tirzepatide on cardiac structure and function with the underlying hypothesis that it would reduce left ventricular (LV) mass a…
-
66.
Current treatment options for youth-onset type 2 diabetes are limited and have demonstrated lower glycaemic efficacy than those for adult-onset type 2 diabetes. We aimed to assess the safety and efficacy of tirzepatide, a glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, compared with placebo in youth-onset type 2 diabetes. We conducted a phase 3, double-blind, placebo-controlled, multicentre (39 sites), multinational (eight countries) trial over 30 weeks, followed by an o…
-
67.
Novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulaglutide. Explore mechanisms of glucose control by tirzepatide. Post hoc analyses of fasting biomarkers and multiple linear regression analysis. Forty-seven sites in 4 countries. Three hundred and sixteen subjects with type 2 diabetes. Tirzepatide (1, 5, 10, 15…
-
68.
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of tirzepatide versus titrated insulin degludec in people with type 2 diabetes inadequately controlled by metformin with or without SGLT2 inhibitors. In this open-label, parallel-group, multicentre (122 sites), multinational (13 countries), phase 3 study, eligible participants (aged ≥18 years) had a…
-
69.
Substantial weight reduction is often associated with loss of muscle mass. Tirzepatide has been associated with significant reductions in body weight in type 2 diabetes trials and a beneficial effect on body fat distribution in the SURPASS-3 MRI substudy. This post-hoc exploratory analysis studied the association of tirzepatide treatment with changes in thigh muscle volume, muscle volume Z score, and muscle fat infiltration, and aimed to contextualise the results using longitudinal MRI data from…
-
70.
In previous SURPASS studies tirzepatide reduced hemoglobin glycated A1c (HbA1c) and body weight and improved markers of insulin sensitivity and β-cell function to a greater extent than comparators. Explore changes in biomarkers of β-cell function and insulin sensitivity and in efficacy profiles in baseline biomarker quartile analyses with tirzepatide compared to semaglutide. Post hoc analysis of SURPASS-2 phase 3 trial (participants randomly assigned to receive weekly subcutaneous tirzepatide or…
-
71.
LY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. We aimed to examine the efficacy and safety of co-stimulation of the GLP-1 and GIP receptors with LY3298176 compared with placebo or selective stimulation of GLP-1 receptors with dulaglutide in patients with poorly controlled type 2 diabetes. In this double-blind, randomised, phase 2 study, patients with ty…
-
72.
We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide's effects on glycemic control, body weight (BW), and cardiometabolic markers. This post hoc analysis compared baseline characteristics and changes in mean HbA1c, BW, waist circumference (WC), lipids, and blood pressure (BP) in 3,792 participants with early-onset versus later-onset T2D at week 40 (A Study of Tirzepatide [LY3298176] in Participants With Type 2 Diabe…
-
73.
Obesity leads to both heart failure with a preserved ejection fraction (HFpEF) and to chronic kidney disease (CKD); CKD may both influence the clinical course of obesity-related HFpEF; and incretin-based drugs may influence renal function. This analysis had dual objectives: 1) to evaluate the influence of CKD on the clinical responses to tirzepatide in patients with obesity-related HFpEF; and 2) to investigate the complexity of tirzepatide-related changes in renal function. For both objectives,…
-
74.
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. In this study, we used continuous glucose monitoring (CGM) to compare the 24 h glucose profile for participants given tirzepatide compared with those given insulin degludec. This substudy of the open-label, parallel-group, phase 3 SURPASS-3 trial, was done at 45 sites across six countries (Hungary, Poland, Romania, Spain, Ukraine, and t…
-
75.
Tirzepatide induces weight reduction but the underlying mechanisms are unknown. This 6-week phase 1 study investigated early effects of tirzepatide on energy intake. Male and female adults without diabetes (n = 114) and a body mass index from 27 to 50 kg per m
-
76.
Tirzepatide substantially reduced hemoglobin A1c (HbA1c) and body weight in subjects with type 2 diabetes (T2D) compared with the glucagon-like peptide 1 receptor agonist dulaglutide. Improved glycemic control was associated with lower circulating triglycerides and lipoprotein markers and improved markers of beta-cell function and insulin resistance (IR), effects only partially attributable to weight loss. Assess plasma metabolome changes mediated by tirzepatide. Phase 2b trial participants were…
-
77.
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-label trial, insulin-naive adults (≥18 years of age) with type 2 diabetes (T2D) uncontrolled on metformin (with or without a sulphonylurea) were randomized 1:1:1:1 to weekly tirzepatide 5 mg, 10 mg or 15 mg or daily insulin glargine at 66 hospitals in China, South Korea, Australia and India. The primary endpoint was non-inferiority of mean change in hemoglobin A1c (HbA1c) from baseline to week 40 after tre…
-
78.
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2. Participants had body mass index (BMI) ≥ 27 kg/m Tirzepatide 10 and 15 mg were associated with statistically significant greater reductions in weight, BMI and HbA1c versus semaglutide. Tirzepatide 15 mg was associated with statistically significant greater odds…
-
79.
To investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirzepatide in Japanese participants with type 2 diabetes (T2D). This phase 1, double-blind, placebo-controlled, parallel-dose, multiple-ascending dose study randomized participants to once-weekly subcutaneous tirzepatide or placebo. The tirzepatide treatment groups were: 5 mg (5 mg, weeks 1-8), 10 mg (2.5 mg, weeks 1-2; 5 mg, weeks 3-4; 10 mg, weeks 5-8), and 15 mg (5 mg, weeks 1-2; 10 mg, weeks 3-6; 15…
-
80.
To assess the efficacy and tolerability of tirzepatide treatment using three different dose-escalation regimens in patients with type 2 diabetes. In this double-blind, placebo-controlled study, patients were randomized (1:1:1:1) to receive either once-weekly subcutaneous tirzepatide or placebo. The tirzepatide dose groups and dose-escalation regimens were: 12 mg (4 mg weeks 0-3; 8 mg weeks 4-7; 12 mg weeks 8-11), 15 mg-1 (2.5 mg weeks 0-1; 5 mg weeks 2-3; 10 mg weeks 4-7; 15 mg weeks 8-11) and 1…
-
81.
To assess the effect of tirzepatide on long-term risk of atherosclerotic cardiovascular disease (ASCVD) among people with obesity or overweight without diabetes from SURMOUNT-1. SURMOUNT-1, a phase 3 trial, evaluated the efficacy and safety of tirzepatide in adults with body mass index ≥30 or ≥27 kg/m Tirzepatide-treated groups demonstrated reductions in cardiometabolic variables over 72 weeks. In participants without a history of ASCVD (N = 2461), the baseline median risk score was low and did…
-
82.
To evaluate the pharmacodynamic effects of tirzepatide, a novel dual glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide receptor agonist, compared with dulaglutide in patients with type 2 diabetes. SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, Phase 3 study, conducted in Japan. This substudy of SURPASS J-mono evaluated postprandial metabolic variables and appetite after a meal tolerance test, and body composition…
-
83.
Tirzepatide reduced weight significantly more than placebo in adults with obesity/overweight who had already achieved ≥5% weight reduction with a 12-week intensive lifestyle intervention (randomized population) in SURMOUNT-3, a phase 3, 72-week, randomized, double-blind clinical trial. This analysis evaluated health-related quality of life (HRQoL) with tirzepatide versus placebo treatment in the SURMOUNT-3 randomized population and selected subgroups. The randomized population received placebo (…
-
84.
To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with type 2 diabetes mellitus (T2DM). Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks. Changes from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST), keratin-18 (K-18), proc…
-
85.
In a clinical study, tirzepatide, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1RA), provided superior glycemic control vs the GLP-1RA semaglutide. The physiologic mechanisms are incompletely understood. This work aimed to evaluate treatment effects by model-based analyses of mixed-meal tolerance test (MMTT) data. A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted a…
-
86.
The SUMMIT trial showed that the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide 1 receptor agonist tirzepatide decreased the risk of cardiovascular death or worsening heart failure (HF) in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Effects may differ by baseline obesity severity, distribution, or magnitude of weight loss. In this analysis, the authors compared baseline characteristics and effects of tirzepati…
-
87.
This analysis evaluated whether gastrointestinal (GI) adverse events (AEs) including nausea, vomiting, diarrhoea (N/V/D) and dyspepsia were associated with weight reduction with tirzepatide across the SURMOUNT-1 to -4 trials. SURMOUNT-1 to -4 were global Phase 3 clinical trials evaluating the safety and efficacy of tirzepatide among participants with obesity or overweight with or without type 2 diabetes (T2D). Participants were randomly assigned to receive once weekly subcutaneous tirzepatide or…
-
88.
To compare the efficacy and safety of tirzepatide 5, 10 and 15 mg with subcutaneous semaglutide 0.5 mg as second-line treatment for adults with type 2 diabetes mellitus, after metformin monotherapy, using adjusted indirect treatment comparisons (aITCs). The aITCs were performed using the Bucher method to compare the relative efficacy and safety of tirzepatide 5, 10 and 15 mg versus semaglutide 0.5 mg via a common comparator (subcutaneous semaglutide 1.0 mg) based on trial results from SURPASS-2…
-
89.
Tirzepatide and semaglutide demonstrated clinically meaningful weight reduction in people with obesity or overweight and type 2 diabetes (T2D) in SURMOUNT-2 and STEP 2 clinical trials, respectively. In the absence of head-to-head trials, this study compared the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison. Mean percent change in weight from baseline, weight reduction ≥5% and mean change in glycated haemoglobin (HbA1c [%]) were compared betwe…
-
90.
To explore the relationship between weight loss and insulin sensitivity in response to tirzepatide or semaglutide. We conducted a post hoc exploratory analysis of a 28-week, double-blind, randomized trial in people with type 2 diabetes treated with metformin, randomized to tirzepatide 15 mg, semaglutide 1 mg or placebo. We evaluated the relationship between change in body weight and change in insulin sensitivity determined from hyperinsulinemic euglycemic clamp (M value), or from mixed-meal tole…
-
91.
Incretin-based therapies are used to treat type 2 diabetes and obesity, but the presence of diabetes diminishes the magnitude of weight loss produced by these drugs in people with obesity. It is not known whether this attenuated weight change is relevant to the clinical benefits of these drugs in heart failure. The goal of this study was to assess the influence of diabetes on the efficacy and safety of tirzepatide in the SUMMIT trial. In a double-blind trial, 731 patients with heart failure and…
-
92.
In SURMOUNT-5, tirzepatide led to greater body weight (BW) reduction versus semaglutide in adults with obesity without T2D. Health-related quality of life (HRQoL) with tirzepatide versus semaglutide in SURMOUNT-5 was evaluated. This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose. Changes in prespecified Short Form-36 Health Survey Version 2 (SF-36v2) norm-based scores for the Physical Component Summary (PCS…
-
93.
We assessed insulin sensitivity and β-cell function in adults with obesity/overweight, without diabetes, treated with tirzepatide for 72 weeks. This post hoc analysis from the Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) trial investigated tirzepatide versus placebo in 2,539 participants with BMI ≥27 kg/m2 and either prediabetes or normoglycemia at baseline. Model-derived parameters of β-cell function and insulin sensitivity were assessed from oral glu…
-
94.
Obstructive sleep apnea (OSA) is a common disorder characterized by repetitive collapse of the upper airway during sleep. Given that excess adiposity is a known risk factor for OSA, we aimed to descriptively assess the association of tirzepatide, a GIP/GLP-1 receptor agonist, with changes in AHI, hypoxic burden, body weight, and blood pressure in different patient populations based on baseline characteristics such as age, sex, BMI, AHI, and neck circumference. These post hoc analyses examined da…
-
95.
Modest body weight reduction can greatly improve many health-related outcomes. In the SURMOUNT clinical trial program, once-weekly tirzepatide resulted in substantial body weight reductions in people with obesity, without and with type 2 diabetes. This post-hoc analysis assessed the proportion of participants achieving body weight reduction thresholds (≥5%, ≥10%, ≥15%), systolic blood pressure reduction ≥5 mmHg, and non-high-density lipoprotein cholesterol (non-HDL-C) <130 mg/dL with tirzepatide…
-
96.
The patatin-like phospholipase 3 (PNPLA3) I148M genetic variant is highly associated with steatotic liver disease. In the SURPASS-3 MRI substudy, tirzepatide significantly reduced liver fat content (LFC) versus insulin degludec in insulin-naïve patients with type 2 diabetes with metabolic dysfunction-associated steatotic liver disease. The influence of PNPLA3 I148M allele on changes in LFC in response to tirzepatide is unknown. This post hoc analysis evaluated changes in MRI-assessed LFC and car…
-
97.
To evaluate the efficacy and safety of tirzepatide versus semaglutide in individuals eligible for pharmacotherapy for obesity disease under Japan's national insurance criteria, where obesity is defined as body mass index (BMI) ≥25 kg/m This subpopulation analysis of the SURMOUNT-5 trial (NCT05822830) included participants meeting obesity disease criteria: hypertension or dyslipidemia with BMI 27-35 kg/m Of 750 participants, 383 met the criteria for obesity disease (tirzepatide 15 mg or maximum t…
-
98.
These post-hoc analyses of SURMOUNT-OSA evaluated patient-reported outcome measures (PROMs) and objective assessments, considering participants' baseline characterization of fatigue, sleepiness, snoring, and sleep quality. SURMOUNT-OSA included two 52-week randomized, placebo-controlled studies of tirzepatide (10/15 mg) in participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity (Study 1: participants not using positive airway pressure [PAP]; Study 2: participants using PAP…
-
99.
Obesity affects over 800 million people globally and is associated with complications including cardiovascular disease and type 2 diabetes (T2D). Early response to weight loss interventions may help optimize achievement of individual treatment goals. Tirzepatide has demonstrated significant weight reduction and improvement in cardiometabolic risk parameters (CRPs) in the SURMOUNT (SM)-1 (NCT04184622) and SM-2 (NCT04657003) trials. We aimed to assess weight reduction, CRPs, tolerability and hypog…
-
100.
SURMOUNT-REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard-of-care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m A 5-year, phase 4, multicenter, open-label, pragmatic randomized clinical trial is enabled through access to participants' integrated electronic healthcare record data. The study will enroll approximately 3000 participants from Greater Manchester, UK, who are randomly assigned in a 1:1 ratio to receive either tirzepatide and S…
-
101.
We report findings from the Chinese SURPASS-CN-MONO trial (ClinicalTrials.gov: NCT05963022) of tirzepatide monotherapy. A multicenter, randomized, double-blind, phase 3 trial conducted at 29 centers in China. Adults with type 2 diabetes who had not received antihyperglycemic medication in the previous 90 days were randomized 1:1:1:1 to receive once-weekly 5, 10, or 15 mg tirzepatide or placebo. The primary endpoint was the mean change from baseline in hemoglobin A1c (HbA1c) at week 40. In total,…
-
102.
Obesity management is central to reducing cardiovascular disease (CVD) risk. In the phase 3 SURMOUNT-J trial, tirzepatide significantly reduced body weight and improved cardiometabolic parameters versus placebo in Japanese adults with obesity disease (as defined by the Japan Society for the Study of Obesity [JASSO], referring to obesity requiring clinical treatment) and without diabetes. We conducted post hoc analyses to predict 10-year CVD risk and the number of potentially preventable CVD even…
-
103.
Loss of lean mass in proportion to total weight loss is observed with incretin mimetic therapies such as tirzepatide and has the potential to adversely affect health and function. Apitegromab is an investigational, fully human monoclonal antibody that selectively inhibits myostatin activation and is, thereby, capable of increasing muscle mass. In the randomized, double-blind, placebo-controlled phase 2 EMBRAZE study, adults with overweight or obesity (n = 102) were randomized 1:1 to receive tirz…
-
104.
This study aimed to assess the effects of low-dose tirzepatide combined with metformin (COM) versus metformin (MET) monotherapy in overweight/obese women with polycystic ovary syndrome (PCOS). Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks. The primary outcome was the change in body weight. Secondary outcomes included changes in anthropometric measures other t…
-
105.
Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for treatment of type 2 diabetes and obesity. The effect of tirzepatide on cardiovascular risk biomarkers in people with overweight or obesity remains uncertain. The purpose of this study was to evaluate the association of tirzepatide compared to placebo on biomarkers that reflect inflammation (high-sensitivity C-reactive protein, interleukin-6, fibrinogen, leukocytes),…
-
106.
Initiation of treatment with tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GLP-1RA), early after a diagnosis of type 2 diabetes (T2D) may establish better and more durable glycemic control than current treatment approaches per guidelines and clinical practice. To assess the efficacy and safety of tirzepatide versus intensified conventional care (ICC) in participants with early T2D who have inadequate glycemic control with di…
Clinical Trials
5-
107.
Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subc…
-
108.
We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medications. This open-label, parallel-group, phase 3 study was done in 187 sites in 14 countries on five continents. Eligible participants, aged 18 years or older, had type 2 diabetes treated with any combination of me…
-
109.
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist used for treatment of type 2 diabetes (T2D) in adults and was recently approved for treatment of obesity. To determine the absorption, distribution, metabolism, and excretion (ADME) of tirzepatide, [
-
110.
SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD. This Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance fro…
-
111.
To identify predictors of body weight (BW) reduction of ≥15% with tirzepatide treatment and to describe associated clinical parameters of participants with type 2 diabetes (T2D) who achieved different categorical measures of BW reduction (<5%, ≥5 to <10%, ≥10 to <15%, and ≥15%) across four studies from the phase 3 SURPASS clinical trial program for T2D. The multivariate model for predictor of a BW reduction of ≥15% included age, sex, race, BW, HbA1c, tirzepatide dose and baseline metformin use,…
Trial Registrations (ClinicalTrials.gov)
169-
112.
Conditions: Type 2 Diabetes
-
113.
Conditions: Obesity and Overweight, HIV, Chronic Inflammation
-
114.
Conditions: Diabetes Mellitus, Type 2, Obesity, Gastroparesis
-
115.
Conditions: Healthy
-
116.
Conditions: Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2 (+5)
-
117.
Conditions: Obesity (Disorder), Breast Cancer
-
118.
Conditions: Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders (+2)
-
119.
Conditions: Obesity and Overweight, Binge Eating Disorder
- 120.
- 121.
-
122.
Conditions: Type 2 Diabetes, Overweight, Obesity
-
123.
Conditions: Type 2 Diabetes Mellitus
-
124.
Conditions: Diabetes Mellitus, Type 2
-
125.
Conditions: Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence (+5)
- 126.
-
127.
Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH) (+2)
-
128.
Conditions: Overweight, Obesity
-
129.
Conditions: Endometrioid Endometrial Adenocarcinoma
- 130.
-
131.
Conditions: Renal Insufficiency, End Stage Renal Disease
-
132.
Conditions: Obesity
-
133.
Conditions: Healthy, Type 2 Diabetes Mellitus (T2DM)
-
134.
Conditions: Overweight, Obesity
-
135.
Conditions: Obesity and Obesity-related Medical Conditions, Bariatric Surgery
- 136.
- 137.
- 138.
- 139.
-
140.
Conditions: Diabetes, Prostate Cancer
-
141.
Conditions: Hidradenitis Suppurativa
-
142.
Conditions: Obesity and Overweight
-
143.
Conditions: Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy
-
144.
Conditions: Overweight , Obesity, Obesity (Disorder)
- 145.
- 146.
-
147.
Conditions: Obesity & Overweight, Weight Loss, Preventative Health (+2)
-
148.
Conditions: Type 2 Diabetes Mellitus
-
149.
Conditions: Psoriatic Arthritis (PsA), Obesity & Overweight
-
150.
Conditions: Type 2 Diabetes
- 151.
-
152.
Conditions: Obesity-related Male Infertility
-
153.
Conditions: Obesity
-
154.
Conditions: Type 2 Diabetes Mellitus
- 155.
-
156.
Conditions: Obesity
-
157.
Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
-
158.
Conditions: COPD, Obesity & Overweight, Sarcopenia
-
159.
Conditions: Obesity (BMI>30)
-
160.
Conditions: Alzheimer Disease, Diabetes Mellitus Type 2, Obesity & Overweight
- 161.
-
162.
Conditions: Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
-
163.
Conditions: Obesity & Overweight, Cardiometabolic Health Indicators, Addiction (+2)
-
164.
Conditions: Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma
-
165.
Conditions: Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
-
166.
Conditions: Obesity
-
167.
Conditions: Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease, Dyslipidaemia (+3)
-
168.
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
-
169.
Conditions: Obesity, Breast Cancer Risk
-
170.
Conditions: Diabetes Mellitus, Type 1, Overweight, Obesity
- 171.
-
172.
Conditions: Obesity
- 173.
- 174.
- 175.
-
176.
Conditions: Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
- 177.
- 178.
-
179.
Conditions: Ulcerative Colitis, Obesity or Overweight
-
180.
Conditions: Chronic Weight Management
- 181.
-
182.
Conditions: Tirzepatide, Frozen Embryo Transfer, Obesity
-
183.
Conditions: Cannabis Use Disorder
-
184.
Conditions: Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
-
185.
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
Conditions: Obesity, Knee Osteoarthritis, Osteoarthritis, Knee
- 186.
-
187.
Conditions: Obesity, Type 2 Diabetes (T2D)
-
188.
Conditions: Obesity
-
189.
Conditions: Obesity & Overweight
-
190.
Conditions: Obesity
-
191.
Conditions: T2DM (Type 2 Diabetes Mellitus)
-
192.
Conditions: Diabetes Mellitus, Type 2, Obesity, Overweight
-
193.
Conditions: Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF), Tirzepatide
-
194.
Conditions: Obesity & Overweight, Diabetes (DM)
-
195.
Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
- 196.
- 197.
-
198.
Conditions: Heart Failure With Preserved Ejection Fraction, Obesity, Diastolic Heart Failure (+2)
-
199.
Conditions: Crohn's Disease, Obesity or Overweight
-
200.
Conditions: Obesity, Adolescent Obesity, Body-Weight Trajectory (+3)
-
201.
Conditions: Obesity (Disorder)
-
202.
Conditions: Obesity, Diabetes Mellitus, Type 2
-
203.
Conditions: Obesity, Overweight
-
204.
Conditions: Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity (+2)
- 205.
-
206.
Conditions: Obesity
-
207.
Conditions: Obesity
-
208.
Conditions: Obese Adults, Hernia Abdominal Wall, Prehabilitation
-
209.
Conditions: Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
-
210.
Conditions: Obesity and Obesity-related Medical Conditions
-
211.
Conditions: Obesity (Disorder)
-
212.
Conditions: Obesity, Methamphetamine Use Disorder, Cocaine Use Disorder (+1)
-
213.
Conditions: Obesity (Disorder), Anti-obesity Agents, Precision Medicine
-
214.
Conditions: Obesity (BMI Equal to or >30)
- 215.
-
216.
Conditions: Central Centrifugal Cicatricial Alopecia (CCCA)
-
217.
Conditions: Post-Bariatric Hypoglycemia
-
218.
Conditions: Obesity &Amp; Overweight, Digestive Disorders
-
219.
Conditions: Type 2 Diabetes, Overweight, ASCVD
-
220.
Conditions: Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity (+1)
-
221.
Conditions: Obesity
-
222.
Conditions: Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D (+2)
-
223.
Conditions: Psoriatic Arthritis, Overweight or Obesity
-
224.
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
Conditions: Atrial Fibrillation, Obesity & Overweight, Catheter Ablation
-
225.
Conditions: Methamphetamine Use Disorder
-
226.
Conditions: Cannabis Use Disorder
- 227.
-
228.
Conditions: Obesity
- 229.
-
230.
Conditions: Atrial Fibrillation Ablation, Persistent Atrial Fibrillation, Obesity & Overweight
-
231.
Conditions: Steatosis of Liver, Metabolic Liver Injury, Obesity (+2)
-
232.
Conditions: Neuropathy, Small Fiber, Diabete Mellitus
-
233.
Conditions: Heart Failure and Reduced Ejection Fraction, Obesity & Overweight, Tirzepatide
-
234.
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
Conditions: Healthy Subjects, Obesity, Type 2 Diabetes
-
235.
Conditions: Longevity, Preventive Medicine, Biological Ageing
-
236.
Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
Conditions: Acute Lymphoblastic Leukemia, Obesity
- 237.
- 238.
-
239.
Conditions: Diabetes Mellitus
-
240.
Conditions: Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder
-
241.
Conditions: Obesity, Sarcopenia
-
242.
Conditions: Prostate Carcinoma, Recurrent Prostate Carcinoma
-
243.
Conditions: Alcohol Use Disorder (AUD)
-
244.
Conditions: Obesity, Overweight and/or Obesity, Overweight (+1)
-
245.
Conditions: Alcohol Use Disorder (AUD)
-
246.
Conditions: Endometrial Cancer, Obesity
-
247.
Conditions: Idiopathic Intracranial Hypertension (IIH)
-
248.
Conditions: Smoking Cessation, Smoking Behaviors
-
249.
Conditions: Severe Obesity, Obesity, BMI Greater Than 30
-
250.
Conditions: Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
-
251.
Conditions: Class I Obesity
-
252.
Conditions: Obesity, Weight Gain
-
253.
Conditions: Obesity, Methamphetamine Use Disorder
-
254.
Conditions: MASLD, Obesity
-
255.
Conditions: Type 1 Diabetes Mellitus
-
256.
Conditions: Acute Ischemic Stroke (AIS)
- 257.
-
258.
Conditions: Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, Inflammatory
-
259.
Conditions: Obesity / Overweight
-
260.
Conditions: Endometrial Cancer
-
261.
Conditions: Obesity, Overweight
- 262.
-
263.
Conditions: Lactation, Weight Loss
-
264.
Conditions: Sleep Apnoea, Obesity & Overweight, Sleep Apnea Syndrome, Obstructive
-
265.
Conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
-
266.
Conditions: Obesity, Menopause Hot Flashes
-
267.
Conditions: Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
-
268.
Conditions: Obesity
-
269.
Conditions: Obesity and Obesity-related Medical Conditions
-
270.
Conditions: Type 2 Diabetes Mellitus, Obesity
-
271.
Conditions: GLP-1 Receptor Agonist Treatment
-
272.
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease
-
273.
Conditions: Overweight, Obesity, Type 2 Diabetes
-
274.
Conditions: Hormone-receptor-positive Breast Cancer, Early Breast Cancer
-
275.
Conditions: Overweight, Obesity, Chronic Kidney Disease (+2)
-
276.
Conditions: Obese Diabetics, Obese Non Diabetic
-
277.
Conditions: Non-diabetec Obesity, Obesity (Disorder)
-
278.
Conditions: Crohn Disease (CD)
-
279.
Conditions: Obesity, Menopause
-
280.
Conditions: Obesity (Disorder)
Reviews
27-
281.
Tirzepatide (Mounjaro
-
282.
Tirzepatide is a once-weekly dual agonist, acting on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is approved at the same doses (5, 10 and 15 mg) for both type 2 diabetes (T2D) and chronic weight management. Following a search in PubMed, clinicaltrials.gov, conference abstracts and Lilly website, we review herein the global phase 3 SURMOUNT program on tirzepatide's safety and efficacy for chronic weight management. Additionally, we discuss…
-
283.
Glucagon-like peptide-1 (GLP-1) receptor agonists improve glucose homeostasis, reduce bodyweight, and over time benefit cardiovascular health in type 2 diabetes mellitus (T2DM). However, dose-related gastrointestinal effects limit efficacy, and therefore agents possessing GLP-1 pharmacology that can also target alternative pathways may expand the therapeutic index. One approach is to engineer GLP-1 activity into the sequence of glucose-dependent insulinotropic polypeptide (GIP). Although the the…
-
284.
The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss. Tirzepatide is the first dual GLP-1/GIP receptor co-agonist which has been approved for treatment of type 2 diabetes mellitus (T2DM) based on the findings from the SURPASS program. The SURPASS trials assessed the safety and efficacy of tirzepatide in people wit…
-
285.
Tirzepatide is a twincretin recently approved to improve glycemic control in type 2 diabetes mellitus (T2DM). More specifically, tirzepatide is an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP1) receptors. In recent clinical trials in persons with obesity or overweight with associated conditions, tirzepatide decreased body weight and other cardiorenal risk factors (blood pressure, low-density lipoprotein cholesterol, glycated hemoglob…
-
286.
Tirzepatide is a first-in-class dual agonist at receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) for the treatment of T2D and obesity, with unprecedented efficacy for glycaemic control, reductions in body weight and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists. To date, clinical trials of tirzepatide have fulfilled the requirement by regulatory authorities of demonstrated cardiovascular safe…
-
287.
Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved by the US Food and Drug Administration in May 2022 for patients with type 2 diabetes mellitus (T2DM). We aimed to determine the rates of individual adverse events (AEs) related to 3 studied doses of tirzepatide. We performed a systematic review with meta-analysis including 5 databases (PubMed, Embase, CINAHL, Scopus, and Web of Science) for all clinical trials rep…
-
288.
Tirzepatide (Mounjaro™) is a single molecule that combines dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Native GIP and GLP-1 are incretin hormones that stimulate insulin secretion and decrease glucagon secretion. GIP also plays a role in nutrient and energy metabolism, while GLP-1 also delays gastric emptying, supresses appetite and improves satiety. Eli Lilly is developing tirzepatide for the treatment of type 2 diabetes melli…
-
289.
Globally, cardiovascular diseases (CVDs) account for around one-third of all deaths. Clinical trial evidence suggests that treatment of people with obesity or type 2 diabetes (T2D) and CVD with glucagon-like peptide-1 (GLP-1) receptor agonists reduces the risk of major adverse cardiovascular events, heart failure outcomes and all-cause mortality. Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that has demonstrated dose-dependent e…
-
290.
This commentary aims to offer a perspective on the effect of tirzepatide on hypoxic burden and provide indirect evidence of cardiovascular risk reduction after tirzepatide for the treatment of obstructive sleep apnea and obesity. It also discusses the role of tirzepatide-induced weight loss in the management of obstructive sleep apnea. In the SURMOUNT-OSA phase 3 trials, tirzepatide, a new GIP/GLP-1 receptor co-agonist, reduced the apnea-hypopnea index, hypoxic burden, and body weight in adults…
-
291.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that modulates glucose metabolism and insulin secretion. Recent translational and clinical research has evaluated the effects of GLP-1 receptor agonists (GLP-1 RAs), a class of drugs that mimic the action of native GLP-1 in the central nervous system (CNS). In addition to the efficacy of GLP-1 for the treatment of diabetes mellitus and obesity, preliminary evidence indicates GLP-1s have neuroprotective, therapeutic, and disease modification…
-
292.
Obesity and type 2 diabetes mellites (T2DM) are intertwined epidemics that continue to pose significant challenges to global public health. We aim to review the available evidence on the metabolic effects of tirzepatide, focusing on weight loss and maintenance of lost weight, body composition alterations, appetite regulation, glycemic control, and lipid profile modulation. Tirzepatide administration for 72 weeks elicited significant weight reduction ranging from 5 % to 20.9 % across different tr…
-
293.
Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and gastric inhibitory polypeptide (GIP) receptors. This drug has demonstrated great potential in improving the clinical outcomes of patients with type 2 diabetes. It can lead to weight loss, better glycemic control, and reduced cardiometabolic risk factors. GLP1 receptor agonists have been proven effective antidiabetic medications with possible cardiovascular benefits. Even though they have been proven to reduce the risk of major…
-
294.
The prevalence of obesity and diabetes is an increasing global problem, especially in developed countries, and is referred to as the twin epidemics. As such, advanced treatment approaches are needed. Tirzepatide, known as a 'twincretin', is a 'first-in-class' and the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist, that can significantly reduce glycemic levels and improve insulin sensitivity, as well as reducing body weight by more th…
-
295.
Lipedema is a chronic, progressive adipose tissue disorder that affects up to 10% of women and is characterized by disproportionate lower-limb fat accumulation, pain, edema, and resistance to conventional weight-loss approaches. Its pathophysiology involves a complex interplay of adipocyte hypertrophy, chronic inflammation, extracellular matrix fibrosis, mitochondrial dysfunction, and sex steroid imbalance, highlighting the need for disease-modifying therapies. This narrative review synthesizes…
-
296.
Diabetes mellitus is an increasingly common long-term metabolic disease. There are many treatment options available to manage type 2 diabetes and reduce the risk of associated long-term microvascular and macrovascular complications. The management of type 2 diabetes initially focuses on lifestyle changes, such as a healthy diet and increased physical activity levels, with pharmacological intervention used as an adjunct where necessary. Tirzepatide, sold under the brand name Mounjaro, is the late…
-
297.
Obesity is a chronic disease with significant global health repercussions. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1RAs) are now established as evidence-based options for long-term obesity management. This review compares semaglutide and tirzepatide aims to support precise, equitable, and durable care for people with the disease of obesity. This review provides clinicians with a comparative analysis of semaglutide (Ozempic) and tirzepatide (Mounjaro) in o…
-
298.
One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D). Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i). Tirzepatide represents a first-in-class agent as a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP1RA to be approved in the USA and Europe for the treatment…
-
299.
This review evaluates the comparative efficacy of bariatric surgery and pharmacological interventions targeting Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptors. Recent advancements, including the FDA approval of Tirzepatide (Zepbound) for OSA, are critically analysed alongside existing literature, offering insights into physiological mechanisms, long-term outcomes, and patient selection criteria. OSA is a chronic condition characterized by repetit…
- 300.
-
301.
Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a groundbreaking treatment for Type 2 diabetes mellitus (T2DM) and obesity. Initially developed for glycemic control, recent clinical and preclinical data reveal its broader therapeutic potential across a range of metabolic and systemic conditions. This review explores tirzepatide's mechanisms of action, clinical efficacy, and safety profile, with part…
-
302.
It is a well-accepted fact that obesity and diabetes increase the risk of incidence of different cancers and their progression, leading to a decrease in the quality of life among affected cancer patients. In addition to decreasing the risk of cancers, maintaining a healthy body mass index (BMI)/body weight and/or blood glucose levels within the normal range critically impacts the response to anti-cancer therapy among affected individuals. A cancer patient managing their body weight and maintaini…
-
303.
Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, recently commercialized and reimbursed in Belgium for the treatment of type 2 diabetes (T2D). Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg as a once-weekly subcutaneous injection), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, se…
-
304.
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, lowers high-sensitivity C-reactive protein (hsCRP) by 29-55% across randomised trials in obesity, heart failure with preserved ejection fraction and obstructive sleep apnoea, and interleukin-6 by 25-30% at 72 weeks. Much of this is not weight-mediated: in SURPASS-4 the fall in hsCRP correlated with that in body mass index at r = 0.07, and mediation analysis of trials of se…
-
305.
Heart failure with preserved ejection fraction (HFpEF) accounts for over half of all heart failure hospitalizations and is increasing in prevalence, largely driven by obesity and type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual GLP-1/GIP agonist, tirzepatide, have been shown to be safe and effective medications in the treatment of T2DM and obesity, as well as in obesity-related HFpEF. This review summarizes the pathophysiology of obesity-related…
-
306.
This review describes the updated pharmacology of antidiabetic drugs and its translation into clinical applications. English language literature published from January 1, 1998 to July 25, 2026 was collected using PubMed, ScienceDirect, and Ovid. Research articles, reviews, and clinical practice guidelines were included for discussion. Currently, ultra-long-acting basal insulins are emerging, allowing less frequent injections. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), tirzepatide, and…
-
307.
Currently, there are no available guidelines for switching from semaglutide to tirzepatide, since the mechanisms of action and pharmacokinetics differ, thus posing a challenge for continuous treatment of obesity. A narrative review of PubMed, Embase, and ClinicalTrials.gov (to May 2026) evaluated trials and cohorts comparing semaglutide (0.25-7.2 mg) and tirzepatide (2.5-15 mg). We synthesized indirect treatment comparisons to outline dose-response relationships and develop approximate efficacy‑…
Research Articles
139-
308.
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis. Early phase trials in T2DM indicate that tirzepatide improves clinical outcomes beyond those achieved by a selective GLP-1 receptor agonist. Therefore, we hypothesized that the integrated potency and signaling properties of tirzepatide provide a unique pharmacological profile tailored for improving broad metabolic cont…
-
309.
Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is a chronic and progressive illness. Millions of Americans have T2DM and many patients do not achieve the recommended blood glucose levels. Glucagon-like peptide 1 (GLP-1) based therapy is an established treatment for the management of T2DM and is recommended early in the treatment algorithm. GLP-1 therapy is associated with better glycemic control, weight reduction, and favorable cardiovascular outcomes. Tirzepatide (Mounj…
-
310.
Heart failure with preserved ejection fraction (HFpEF) is a major cause of hospitalization, often occurring in patients with cardiometabolic comorbidities such as obesity and type 2 diabetes. Although early trials of semaglutide and tirzepatide have shown promising results in improving symptoms, those findings were based on few clinical events, leaving treatment recommendations uncertain. To evaluate the effectiveness and safety of semaglutide and tirzepatide in patients with cardiometabolic HFp…
-
311.
Tirzepatide (LY3298176), a dual GIP and GLP-1 receptor (GLP-1R) agonist, delivered superior glycemic control and weight loss compared with GLP-1R agonism in patients with type 2 diabetes. However, the mechanism by which tirzepatide improves efficacy and how GIP receptor (GIPR) agonism contributes is not fully understood. Here, we show that tirzepatide is an effective insulin sensitizer, improving insulin sensitivity in obese mice to a greater extent than GLP-1R agonism. To determine whether GIPR…
-
312.
Tirzepatide is a first-in-class glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved as for the treatment of type 2 diabetes mellitus. A population-based pharmacokinetic (PK) model was developed from 19 pooled studies. Tirzepatide pharmacokinetics were well-described by a two-compartment model with first order absorption and elimination. The tirzepatide population PK model utilized a semimechanistic allometry model to describe the relationship betwee…
-
313.
Sepsis-induced cardiac dysfunction is a leading cause of mortality in intensive care units. Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, possess cardio-protective, their effects on sepsis-induced cardiomyopathy remain unknown. C57BL/6 mice received subcutaneous injections of tirzepatide once a day for 14 days before subjected to LPS challenge for 12 h. LPS-induced cardiac dysfunction and its potential mechanisms were…
-
314.
Tirzepatide (LY3298176), a GLP-1 and GIP receptor agonist, is fatty-acid-modified and 39-amino acid linear peptide, which ameliorates learning and memory impairment in diabetic rats. However, the specific molecular mechanism remains unknown. In the present study, we investigated the role of tirzepatide in the neuroprotective effects in Alzheimer's disease (AD) model mice. Tirzepatide was administrated intraperitoneal (i.p.) APP/PS1 mice for 8 weeks with at 10 nmol/kg once-weekly, it significantl…
-
315.
Approximately two-thirds of obesity-related mortality is attributable to cardiovascular disease (CVD). The aim of this analysis is to examine predicted CVD risk reduction following weight loss in persons with obesity for primary prevention between tirzepatide and semaglutide, and projected CVD events that could be potentially prevented in the USA. SURMOUNT-5 was a Phase 3b, open-label, randomized trial conducted in participants with obesity and without Type-2 diabetes, comparing tirzepatide (10…
-
316.
To compare the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison. Using SURMOUNT-1 and STEP 1 trial data, mean percentage change in body weight from baseline and odds ratio (OR) of achieving 5% or greater weight loss were compared between tirzepatide 10 and 15 mg at week 72 and semaglutide 2.4 mg at week 68 using matching-adjusted indirect comparison of the efficacy estimand. Sensitivity analyses were completed using different methods, including…
-
317.
People with obesity and/or type 2 diabetes are at higher risk of progressive kidney function loss. We assessed the association of tirzepatide use with kidney function parameters in people with overweight/obesity with or without type 2 diabetes. Tirzepatide treatment was associated with urine albumin-to-creatinine reduction after 24 weeks, which was sustained through week 72, and no change in eGFR. Tirzepatide, a once-weekly, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-…
-
318.
The effect of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide on gastric emptying (GE) was compared to that of GLP-1RAs in non-clinical and clinical studies. GE was assessed following acute and chronic treatment with tirzepatide in diet-induced obese mice versus semaglutide or long-acting GIP analogue alone. Participants [with and without type 2 diabetes (T2DM)] from a phase 1, 4-week multiple dose study received tirze…
-
319.
Obesity and type 2 diabetes mellitus (T2DM) are significant global health challenges, with adipose tissue inflammation being a pivotal contributor to metabolic dysfunction. The involvement of adipose tissue macrophages (ATMs) in obesity-associated inflammation is well recognized, yet the therapeutic strategies specifically targeting ATM-mediated inflammation remain limited. This study aims to explore the effects of tirzepatide, a novel dual GLP-1 and GIP receptor agonist, on ATMs, adipose tissue…
-
320.
Tirzepatide, a dual agonist of glucagon-like peptide receptor and glucose-dependent insulinotropic polypeptide receptor, is expected to exhibit high clinical efficacy in obese type 2 diabetic patients. We evaluated the effects of tirzepatide on pancreatic β-cells and the liver, an insulin-target organ, in a mouse model of obese type 2 diabetes mellitus. Obese type 2 diabetic db/db mice (BKS.Cg-/+ Leprdb/+ Leprdb/Jcl*) were used in this study. Starting at 7 weeks of age, mice were treated with ti…
-
321.
Cardiovascular outcome trials of the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with varying levels of cardiovascular risk. However, without direct head-to-head comparisons, treatment decisions rely on indirect evidence from heterogeneous trial populations, leaving optimal treatment choices uncertain. Here we conducted five cohort studies to assess the effectiveness of tirzepatide and semaglutide in patients with elevated cardiovascular risk, includin…
- 322.
-
323.
OSA is a prevalent chronic condition linked to obesity that is associated with increased risks of cardiovascular and kidney disease. Although weight loss can improve OSA outcomes, additional effective therapeutic options are needed. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has shown promise in promoting significant weight loss and reducing OSA severity. Does tirzepatide affect clinical outcomes in individuals with OSA and obes…
-
324.
Obesity, a chronic disease with escalating global prevalence, poses considerable health risks. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, have demonstrated efficacy for weight loss in clinical trials. The paradigm shift in the approach to obesity management drugs (OMDs) may offer an opportunity to examine online search activity and prescription trends. To investigate prescription patterns and online search trends for OMD and correla…
-
325.
Semaglutide 2.4 mg injection (Wegovy This retrospective cohort study included adults with overweight or obesity and ≥ 1 pharmacy claim for semaglutide 2.4 mg or tirzepatide in the US Komodo Health database between June 4, 2021, and December 15, 2023. Patients had continuous enrollment for 1 year before (baseline period) and 1 year after (follow-up period) the index date (date of treatment initiation) and persistence on therapy (no gap of > 30 days' supply) during follow-up. Patients with T2DM at…
-
326.
Effective therapeutic approaches for the treatment of diabetic nephropathy (DN) with irreversible deterioration of renal function are currently lacking. In this study, we aimed to investigate the ability of the glucagon-likepeptide-1 (GLP-1)/ gastric inhibitory polypeptide (GIP) dual agonist, tirzepatide to alleviate DN in mice and its underlying mechanisms. We investigated the reno-protective effect of semaglutide and tirzepatide in a mouse model of DN, an insulin-treated positive control group…
-
327.
In recent years, there has been a dramatic increase in the popularity and use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss. As such, it is essential to understand users' real-world discussions of short-term, long-term, and co-occurrent adverse events associated with currently used GLP-1 RA medications. This study aims to quantitatively analyze temporal and co-occurrent GLP-1 RA adverse event trends through discussions of GLP-1 RA weight loss medications on Facebook fr…
- 328.
- 329.
-
330.
While cardiovascular benefits of tirzepatide, a glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes mellitus (T2DM), and its comparative effectiveness vs glucagon-like peptide-1 receptor agonists (GLP-1RAs) is studied in randomized controlled trials, real-world outcomes may provide critical insights. The purpose of this study was to examine the cardiovascular benefits of tirzepatide vs GLP-1RA in people living with overweight or obes…
-
331.
Interventions that combat obesity and its associated metabolic perturbations may decrease incidence and improve outcomes of endometrial cancer (EC). Potential options for weight loss include pharmacotherapeutic interventions such as tirzepatide, a dual-acting glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist. Given this, we explored the anti-obesity and anti-tumorigenic effects of tirzepatide in our pre-clinical mouse model of endometrioid EC. Starting at…
-
332.
Glucagon-like peptide-1 receptor agonists (GLP1RAs) lead to substantial weight loss and pain reduction in persons with knee osteoarthritis and obesity. To evaluate the cost-effectiveness of 2 GLP1RAs, semaglutide and tirzepatide, for patients with osteoarthritis and obesity. Osteoarthritis Policy Model, a validated microsimulation model of knee osteoarthritis, to estimate lifetime benefits and costs of weight loss strategies. Published data to derive treatment-related weight loss, pain reduction…
-
333.
The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate glucose tolerance
-
334.
To understand real-world tirzepatide utilization and effectiveness (change in weight and body mass index [BMI]) among people without type 2 diabetes (T2D) in the United States. This retrospective, observational study used Optum's de-identified Market Clarity database (index date: first-observed tirzepatide claim; index period: 13 May 2022-30 September 2023). Outcomes were assessed in 3 cohorts: (1) Overall cohort: age ≥18 years; ≥1 tirzepatide claim; no baseline T2D diagnosis codes, anti-diabete…
- 335.
-
336.
Increases in adiposity and adverse changes in adipose distribution commonly occur in women during midlife and with the onset of menopause. This post hoc analysis assessed body weight changes with tirzepatide by reproductive stage. Women participants from SURMOUNT-1, -3, and -4 randomized to tirzepatide (15 mg or maximum tolerated dose) or placebo were retrospectively categorized as being in the pre-, peri-, or post-menopause stages. Body weight and waist circumference changes, the proportion of…
-
337.
The comparative gastrointestinal safety across glucagon-like peptide-1 receptor agonists and tirzepatide is still unclear. To compare the risk for severe gastrointestinal adverse events across dulaglutide, subcutaneous semaglutide, and tirzepatide in patients with type 2 diabetes (T2D) in routine clinical practice. New-user, active-comparator cohort study. Population-based study. Adults with T2D initiating dulaglutide, subcutaneous semaglutide, and tirzepatide between 1 January 2019 and 30 Augus…
-
338.
We report for the first time an anticancer benefit of tirzepatide-a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist-in a model of obesity and breast cancer in female mice. Long-term tirzepatide treatment induced weight loss, mitigated obesity-driven changes in circulating metabolic hormone levels, and suppressed orthotopic E0771 mammary tumor growth. Relative to tirzepatide, chronic calorie restriction, an established anticancer intervention in prec…
-
339.
To assess and compare the therapeutic efficacy of Liraglutide, Tirzepatide, and Retatrutide in treating diabetic kidney disease (DKD) in db/db mice. Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks. Subsequently, we assessed the effectiveness of these three drugs in controlling blood glucose levels, reducing weight, and improving serum biochemical indicators and DKD. Additionally, we measured…
- 340.
-
341.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, delivered superior glycemic control and weight loss compared to selective GLP-1 receptor (GLP-1R) agonism in patients with type 2 diabetes (T2D). These results have fueled mechanistic studies focused on understanding how tirzepatide achieves its therapeutic efficacy. Recently, we found that treatment with tirzepatide improves insulin sensitivity in humans with T2D and obese mice in concert with a reduction in circulating levels of branched-chai…
-
342.
Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and is a promising therapeutic option for type 2 diabetes mellitus (T2DM). Nevertheless, its effect and underlying mechanism on hepatic steatosis remain ambiguous. Herein, we explored the impact of tirzepatide on improving hepatic steatosis in diabetic mice, with a particular focus on the gut microbiota and bile acids (BAs) using animal models. The tirzepatide effecti…
-
343.
Early worsening of diabetic retinopathy (EWDR) has been described during treatment with glucagon-like peptide-1 receptor agonists including subcutaneous semaglutide. Whether EWDR occurs after initiating treatment with the potent glucagon-like peptide 1 / gastric inhibitory polypeptide receptor agonist tirzepatide is unknown. In this retrospective cohort study using real-world clinical data, we matched 3435 tirzepatide-exposed (≥180 days treatment) individuals with type 2 diabetes 1:1 with 3434 t…
-
344.
Tirzepatide, a modified protein containing 39 amino acids, acts as a dual agonist at the gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, showing great promise in weight-loss treatment. While rare, there have been reports of hepatotoxicity associated with tirzepatide use, and the exact mechanism of liver injury remains unclear. This case report highlights the experience of a 24-year-old female schoolteacher who started her weight-loss journey with tirzepatide.…
-
345.
A novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist, tirzepatide (LY3298176, TZP), has been developed to treat Type 2 diabetes mellitus (T2DM). In ischaemic heart diseases, TZP is involved in cardiac metabolic processes. However, its efficacy and safety in treating heart failure (HF) following myocardial infarction (MI) remain uncertain. Herein, 12 week C57BL/6J mice were subjected to MI surgery, followed by administration of TZP. The effects of…
-
346.
To evaluate the association between tirzepatide and the risk of developing erectile dysfunction (ED) in men with type 2 diabetes (T2D), compared with sitagliptin, injectable semaglutide, and dulaglutide. This retrospective cohort study used the TriNetX global health research network from May 13, 2022 to May 17, 2025. Male patients aged 18-70 with T2D and no prior ED were included. Three 1:1 propensity score-matched comparisons were conducted: tirzepatide vs. sitagliptin, injectable semaglutide,…
-
347.
This real-world study compared clinical outcomes between tirzepatide treatment and bariatric metabolic surgery (BMS) in adults with obesity. This retrospective cohort study used the TriNetX network to identify adults with a body mass index (BMI) ≥ 30 kg/m After exclusions and 1:1 propensity score matching (PSM), 84 884 matched pairs were analysed. The incidence of all-cause mortality was 0.19 per 100 person-years in the tirzepatide group compared with 0.57 in the BMS group. Tirzepatide was assoc…
-
348.
Tirzepatide (Mounjaro) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist increasingly prescribed for type 2 diabetes and obesity due to its efficacy in weight loss and glycaemic control. In US FDA-reviewed clinical trials, pancreatitis occurred rarely, at rates of approximately 0.32-0.39% across all doses, comparable to placebo groups. Nevertheless, concerns remain about potential drug-associated pancreatitis, with case reports desc…
-
349.
Recent trends in use of tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptor agonist (RA), versus other glucose-lowering medications (GLMs) and weight-lowering medications (WLMs) remain unexplored. To describe trends in insurance claims for GLMs and WLMs after tirzepatide approval. Population-based cohort study. Claims data from a large U.S. commercial database (January 2021 to December 2023). Adults (aged ≥18 years) with type 2 diabetes (…
- 350.
- 351.
- 352.
-
353.
To evaluate real-world hemoglobin A1c (HbA1c) and weight change in adults initiating treatment with tirzepatide (dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1 RA]) or injectable semaglutide (GLP-1 RA) indicated for type 2 diabetes (T2D) management. This retrospective analysis utilized the Healthcare Integrated Research Database® to identify adults with T2D starting tirzepatide or injectable semaglutide between May 13, 2022 and May 29, 2023.…
- 354.
-
355.
In this study, we aim to explore the effects of tirzepatide on the gut microbiota in mice with obesity induced by a high-fat diet. Forty male C57BL/6J mice, aged six weeks, were randomly assigned to one of four experimental groups: normal control diet, normal control diet with tirzepatide treatment (NCD + TZP), high-fat diet and high-fat diet with tirzepatide treatment (HFD + TZP). Mice in the HFD group were fed a high-fat diet for ten weeks to establish an obesity model. Subsequently, the NCD +…
-
356.
The prevailing treatment of Parkinson's disease (PD) is not yet satisfactory. The present investigate the neuroprotective effect of the GLP-1/GIP dual agonist tirzepatide and examine the potential mechanisms involved. Analysis of GLP1 receptor (GLP1R) and GIPR expression alterations in dopaminergic neurons from PD patients in the GSE238129 dataset. The MPTP-induced subacute PD mice was treated with tirzepatide, semaglutide and levodopa. Behavioral tests and brain histopathology of mice were eval…
-
357.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by excessive hepatic lipid accumulation. This study evaluated the therapeutic effects and molecular mechanisms of tirzepatide, a dual GIP and GLP-1 receptor agonist, in treating hepatic steatosis. Eight-week-old C57BL/6J mice were fed either a high-fat diet or a high-fat, high-fructose, and high-cholesterol diet for 12 weeks to induce MASLD. From week 8, some mice received weekly intraperitoneal tirzepatide injections fo…
-
358.
This cross-sectional study examined associations between self-reported taste perception changes and appetite-related outcomes in individuals with obesity treated with glucagon-like peptide-1 receptor agonist (GLP-1 RAS) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAS in real-world conditions. Four hundred and eleven adults on Wegovy® (n = 217), Ozempic® (n = 148) and Mounjaro® (n = 46) completed an online survey assessing sociodemographic, anthropometric and sensory changes…
-
359.
Obesity and its cardiovascular complications are major causes of morbidity and mortality. Little is known in real-world settings about the effect of newly approved antiobesity medications (AOMs) on cardiovascular complications among patients with obesity. This retrospective cohort study examined the association between newly approved AOM use and cardiovascular events among Medicare patients with obesity using data from 2020 to 2022. Patient age, gender, comorbidity scores, socioeconomic status,…
-
360.
Large telehealth companies and smaller aesthetic medicine providers used compounded semaglutide and tirzepatide to meet consumer demand for these drugs during their shortages. In this study, we estimate the documentation rate of compounded formulations of these drugs in the US primary care and characterize differences between users of compounded and brand-name formulations of these drugs. We conducted a retrospective cohort study using data from the American Family Cohort, a nationwide US databa…
- 361.
- 362.
-
363.
Tirzepatide is usually undetectable in breastmilk with subcutaneous doses of up to 5 mg. Furthermore, absorption by the infant is unlikely because it is probably partially destroyed in the infant's gastrointestinal tract and poorly absorbed orally. If a mother requires tirzepatide, it is not a reason to discontinue breastfeeding. Until more data become available, tirzepatide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
-
364.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity treatment, yet weight-loss outcomes remain highly uneven in real-world care. Using a federated biomedical platform, we analyzed 135 349 individuals treated with semaglutide and tirzepatide formulations and stratified them as "super responders" (>15% weight loss), "moderate responders" (5%-15% weight loss), "minimal weight-loss group" (<5% weight loss), and "weight regainers." Ozempic, Wegovy, Mounjaro, and Zepbound had si…
- 365.
- 366.
-
367.
<h4>Background</h4>Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is highly effective for glycaemic control and weight reduction. However, its real-world cardiovascular adverse event reporting profile remains incompletely characterised.<h4>Methods</h4>We conducted a retrospective pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) from the second quarter of 2022 (FDA approval of tirzepatide) th…
-
368.
<h4>Background</h4>Despite the clinical efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight loss, real-world persistence remains substantially lower than seen in clinical trials. Since 2021, GLP-1RA shortages and changes in product availability have complicated access and persistence.<h4>Objective</h4>To describe by calendar year of initiation the 1-year treatment persistence and adherence trends among commercially insured members without diabetes newly initiating high-po…
- 369.
-
370.
<h4>Aims</h4>To assess the real-world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.<h4>Materials and methods</h4>This retrospective, observational cohort study used Komodo Research Data and included patients ≥45 years of age with overweight/obesity and ≥1 claim for myocardial infarction (MI), i…
- 371.
-
372.
<h4>Introduction</h4>Obesity and its downstream effects continue to drive rising rates of chronic disease. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown significant potential in supporting weight loss and improving metabolic health. This study examines the use of tirzepatide alongside the Individualized Virtual Integrative Medicine (IVIM) protocol. This is a telehealth-based approach to improving outcomes th…
- 373.
-
374.
Obesity is a major public health challenge in the United States, despite widespread implementation of regulated diet plans, exercise programs, behavioral interventions, and surgical procedures. The emergence of incretin-based therapies, particularly GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists, has transformed the therapeutic landscape for initially type 2 diabetes and now obesity. Beyond their metabolic effects, incretin therapies exer…
- 375.
-
376.
[This corrects the article DOI: 10.1210/jcemcr/luaf261.].
-
377.
<h4>Background</h4>Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has gained widespread use for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea. This report presents the first probable case of tirzepatide-associated rhabdomyolysis in a human immunodeficiency virus (HIV)-positive patient.<h4>Case</h4>A 34-year-old male with a medical history of HIV, hypertension, and obesity presented wit…
-
378.
Tirzepatide, a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. Tirzepatide was first approved by the FDA for type 2 diabetes in May 2022 and subsequently for obesity in November 2023, and has demonstrated significant efficacy in glycemic control and weight reduction. Beyond its metabolic benefits, recent evidence highlights its relevance in dermatology. This review explores the dermatologic implications of tirzepatide, including its c…
-
379.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have recently emerged as a promising therapeutic option for patients to aid in weight loss; however, little is known about the potential psychiatric side effects of these medications. In this report, we present the case of a 64-year-old man who was started on the GLP-1 RA tirzepatide (Zepbound) and subsequently developed increased impulsivity, dysphoria, and aggression, which resolved with medication cessation. We suggest a potential relation…
-
380.
<h4>Objectives</h4>The objectives of this case report are to describe the hospitalization of a patient due to a preventable adverse event caused by dulaglutide after restarting therapy following a previous hospitalization where it was held, and to summarize suggested guidance on managing glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) during transitions of care.<h4>Case summary</h4>A 70-year-old female was admitted with epigastric pain that began a week before admission. One month prior,…
-
381.
<h4>Background</h4>More than 80% of patients with heart failure with preserved ejection fraction (HFpEF) are overweight or obese. However, cost-effective treatments that target both conditions remain limited.<h4>Objectives</h4>The goal of this study was to evaluate the cost-effectiveness of tirzepatide compared with standard care alone for the management of HFpEF in patients with obesity in the United States.<h4>Methods</h4>A Markov state-transition model was developed to project clinical and ec…
-
382.
<h4>Introduction</h4>Obesity poses an increasing threat to U.S. military readiness, with over half of active-duty service members classified as overweight and up to 27% with obesity. Within the Military Health System (MHS), obesity contributes to service disqualification, musculoskeletal injury, and cardiometabolic disease, accounting for an estimated $2 billion annually in combined costs. Although TRICARE began covering obesity medications (OMs) in 2018, prior analyses demonstrated limited util…
-
383.
Telehealth has become a mainstream healthcare delivery methods driven by advances in health technology, evolving patient preferences, and the need for more accessible and affordable care. While traditional pharmacy models remain effective, they face numerous challenges, including medication access, patient privacy, and cost efficiency. To understand the impact of telepharmacy and perform a cost-benefit analysis (CBA) in three popular therapeutic areas - obesity, erectile dysfunction, and dermato…
-
384.
<h4>Background</h4>Euglycemic diabetic ketoacidosis (EDKA) is most commonly associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors. However, emerging evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists and dual incretin agents such as tirzepatide (Mounjaro) may also precipitate EDKA, though reports remain rare.<h4>Case report</h4>We report a case of EDKA in a patient on tirzepatide monotherapy, with no concurrent SGLT2 inhibitor use. The patient presented with nau…
-
385.
<h4>Background</h4>Glucagon-like peptide-1 (GLP-1) receptor agonists, including a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist, have expanded treatment options for overweight and obesity. However, real-world data within Medicaid populations remain limited.<h4>Objective</h4>To assess 6-month persistence, adherence, and effectiveness of GLP-1 and GLP-1/GIP therapies among Massachusetts Medicaid (MassHealth) members.<h4>Methods</h4>This retrospective, claims-based analysis…
-
386.
This paper explores the ethical implications of emerging weight-loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications promise significant benefits, including improved individual health outcomes, reduced healthcare costs and, potentially, reduced environmental harms. However, their widespread adoption raises various concerns, such as unknown long-term side effects, t…
-
387.
<h4>Purpose</h4>This study evaluated the cost-effectiveness (from the United States [US] societal perspective) of tirzepatide at its maximum-tolerated-dose (MTD) compared to semaglutide (MTD), both administered adjunct to a reduced-calorie diet and increased physical activity. The analysis focused on individuals with obesity (body mass index [BMI] ≥ 30 kg/m<sup>2</sup>), or overweight (BMI ≥27 to <30 kg/m<sup>2</sup> + ≥1 obesity-related complication), using data from the head-to-head Phase-3 SU…
-
388.
This article examines the growing prevalence of pediatric obesity and its connection to metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents, focusing on the role of glucagon-like peptide-1 receptor agonists in treatment. Pediatric obesity and MASLD present significant long-term health risks, making early intervention crucial. The article reviews the pathophysiology of both pediatric obesity and MASLD, explores current therapeutic strategies, and discusses…
- 389.
-
390.
<h4>Purpose</h4>Tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with rapidly expanding clinical use, requires detailed post-marketing pharmacovigilance to monitor emerging safety signals. This study aims to identify and characterize specific adverse events (AEs) associated with tirzepatide utilizing FDA Adverse Event Reporting System (FAERS).<h4>Patients and methods</h4>The datasets were cleaned and standardized…
-
391.
Tirzepatide has demonstrated greater efficacy than semaglutide in improving glycemic control and reducing body weight in patients with type 2 diabetes mellitus (T2DM). However, the optimal tirzepatide dose following a switch from 1.0 mg of semaglutide remains unclear. This retrospective study included 15 T2DM patients who switched to tirzepatide due to inadequate weight loss. All patients started tirzepatide at 2.5 mg, with escalation to either 7.5 mg (n=10) or 10 mg (n=5). Changes in glycated h…
-
392.
Background The rapid adoption of incretin-based therapies for obesity has raised questions regarding their comparative safety profiles. While the gynecological safety of glucagon-like peptide-1 (GLP-1) receptor agonists is documented, the potential risks associated with dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonism remain less characterized. This study aimed to evaluate the reporting patterns of gynecological hemorrhagic events associated with tirzepatide compared to sema…
-
393.
Obstructive sleep apnea (OSA) is a common disorder characterized by recurrent upper airway collapse during sleep, leading to intermittent hypoxemia and sleep fragmentation. Untreated OSA is associated with increased risks of cardiovascular, metabolic, and neurocognitive comorbidities, as well as considerable socioeconomic burden. Positive airway pressure (PAP) remains the gold standard therapy; however, limited long-term adherence underscores the need for alternative, patient-centered approaches…
- 394.
-
395.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed among plastic surgery patients for obesity and overweight. Agents such as dulaglutide, liraglutide, semaglutide, and tirzepatide differ in pharmacology and dosing, directly influencing perioperative safety, particularly due to their effects on gastric motility and the high frequency of gastrointestinal (GI) adverse events that raise concerns about aspiration and postoperative morbidity in urgent or elective procedu…
-
396.
<h4>Background</h4>Obesity poses a significant public health and economic challenge in the United States (U.S.), with rising prevalence, particularly among individuals enrolled in Medicaid-the nation's public health insurance program for low-income populations. Anti-obesity medications (AOMs) have become integral to managing obesity, but trends in their utilization and spending within Medicaid remain underexplored.<h4>Objective</h4>To examine Medicaid's utilization, reimbursement, and price tren…
-
397.
This sheet is about exposure to tirzepatide in pregnancy and while breastfeeding. This information is based on available published literature. It should not take the place of medical care and advice from your healthcare provider.
-
398.
<h4>Background</h4>Adequately treating obesity remains a fundamental goal for improving quality of life and long-term health outcomes. Semaglutide and tirzepatide have shown clinically meaningful weight loss in clinical trials, yet despite this weight loss efficacy, little is understood about how patients with obesity using semaglutide or tirzepatide experience making dietary behavior change. Furthermore, little is known about their perceptions of obesity treatment and healthcare provider intera…
- 399.
- 400.
-
401.
We present the case of a 52-year-old woman who developed a functional small bowel obstruction despite having no history of abdominal surgery, prior bowel obstruction, or GI interventions. The only notable recent change in her medical history was a dose escalation of Zepbound (tirzepatide), a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide agonist prescribed for weight loss. This case raises concern about potential severe GI motility complications associated with Zepbound, pa…
-
402.
Polycystic ovary syndrome (PCOS) is a widespread condition affecting women of reproductive age. A new class of medications called incretins (GLP1RAs) provides new opportunities for reducing obesity, hyperandrogenism, and insulin resistance in these patients. Promising results have been achieved, including metabolic improvements and benefits in women with PCOS using different GLP1RAs.
-
403.
Biostimulators like hyperdiluted calcium hydroxylapatite-carboxymethylcellulose (CaHA-CMC; Radiesse, Merz North America, Franksville, WI) are effective in promoting neocollagenesis and restoring facial volume. The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1RAs) for weight loss has introduced a subset of patients experiencing rapid weight loss with associated facial-volume changes, colloquially known as "Ozempic Face" (Novo Nordisk, Bagsvaerd, Denmark). This case series d…
- 404.
-
405.
Purpose Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an increasingly prevalent class of drugs for managing overweight/obesity and type 2 diabetes mellitus. Postmarket surveillance is essential for characterizing their risk profiles in real-world patient populations as clinical use increases. This study investigated the association of GLP-1RAs with mortality and serious adverse events (AEs) reported to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Meth…
-
406.
Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, represents a new class of incretin-based therapy for type 2 diabetes mellitus (T2DM), obesity, and related comorbidities. This narrative review synthesizes evidence from the SURPASS, SURMOUNT, and SUMMIT clinical trial programs. Across studies, tirzepatide reduced glycated hemoglobin (HbA1c) by up to 2.5% and body weight by more than 20%. It also improved cardiovascular ri…
-
407.
The introduction of tirzepatide marks a significant advancement in the management of type 2 diabetes mellitus (T2DM) and obesity. This dual synthetic polypeptide, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 receptor agonist (GLP-1 RA) acts through incretin pathways and stimulates insulin sensitivity while slowing gastric emptying. While these benefits are well established, the drug's effects on gastrointestinal motility may predispose susceptible patients to s…
- 408.
-
409.
<h4>Background</h4>Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.<h4>Objective</h4>To comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions.<h4>Methods</h4>A comprehensiv…
- 410.
-
411.
Tirzepatide improves body weight and glycemic control in patients with type 2 diabetes, but factors associated with inter-individual differences after switching remain unclear. We examined whether baseline monocyte glucose-dependent insulinotropic polypeptide receptor (GIPR) mRNA expression was associated with changes in body weight and the fibrosis-4 (FIB-4) index after switching from glucagon-like peptide-1 receptor agonists (GLP-1RAs) to tirzepatide. This single-center retrospective study inc…
-
412.
Metabolic stress, hepatic lipid accumulation, and macrophage-associated sterile inflammation are closely involved in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Tirzepatide improves metabolic outcomes, but its effects on macrophage inflammatory signaling in MASLD remain unclear. This study investigated the protective effects of tirzepatide against high-fat, high-fructose diet (HFHFD)-induced MASLD and examined the potential involvement of macrophage Decti…
-
413.
Tirzepatide (TZP), the first dual GIP/GLP-1 receptor agonist, offers substantial therapeutic benefits for type 2 diabetes mellitus (T2DM) but remains confined to subcutaneous injection. While oral delivery of peptide therapeutics improves patient compliance, it is severely hampered by enzymatic degradation and mucosal barriers in the gastrointestinal tract. Liposomes, as biocompatible nanocarriers, can protect encapsulated drugs, enhance intestinal stability, and enable controlled release. Herei…
-
414.
Comparative cardiovascular data on glucagon-like peptide-1 (GLP-1) agonists versus dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists in atherosclerotic cardiovascular disease (ASCVD) without diabetes are limited. This propensity score-matched retrospective TriNetX study compared adults aged ≥45 years with body mass index ≥27 kg/m After matching, 5665 patients were analyzed per group. No statistically significant differences were observed between semaglutide and tirzepatide i…
-
415.
Weight loss may not reliably improve symptoms or adipose tissue abnormalities in lipoedema. Whether symptom improvement during incretin-based pharmacotherapy is associated with the magnitude of weight loss is unknown. We retrospectively analysed prospectively collected outcomes from 49 women with clinically diagnosed lipoedema treated with tirzepatide in routine care at a specialist clinic between January 2024 and May 2026. The Lipedema Symptom Assessment Questionnaire (QuASiL; range 0-150) was…
-
416.
Real-world evidence on 12-month treatment effectiveness and persistence with tirzepatide remains limited, particularly under individualized dosing and self-funded treatment conditions. We evaluated 12-month tirzepatide outcomes in routine clinical practice. This was a multicenter, retrospective, observational real-world study including 249 adults with overweight or obesity treated with tirzepatide across 13 obesity practices in Greece. Treatment was entirely self-funded, and dose escalation was…
-
417.
GLP-1 and dual GLP-1/GIP receptor agonists have improved obesity treatment, but their high cost requires economic evaluation to guide resource allocation. To assess the short-term cost-effectiveness of subcutaneous tirzepatide, semaglutide, and liraglutide for treating adults with overweight or obesity without diabetes in Iran. A decision-tree model was developed to compare tirzepatide, semaglutide, and liraglutide over 68 weeks in adults aged ≥ 18 years with BMI ≥ 30 kg/m² or ≥ 27 kg/m² with at…
-
418.
While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight reduction, yet most clinical trials lack ethnic diversity, limiting the generalizability of these outcomes. This is a retrospective, single-centre study that evaluates 12-month weight loss…
-
419.
tirzepatide is associated with greater glycemic control and weight reduction compared to semaglutide in patients with T2D. Tirzepatide has also been recently shown to be non-inferior to dulaglutide in cardiovascular risk reduction among patients with T2D. Whether tirzepatide is more or less effective than semaglutide for cardioprotection is underexplored. The Research Collaborative Network of the TriNetX platform was accessed to collect de-identified, real world data on patients with T2D and com…
-
420.
For adults with obesity, fluctuations in body weight are expected to occur during weight management. Weight nadirs, which can become a point of focus for people living with obesity, are often hard to maintain. This study aimed to investigate the not well-defined clinical relevance of weight nadir, especially during long-term treatment with an obesity medication. This was a post hoc analysis of the phase 3, double-blind, randomized, placebo-controlled SURMOUNT-1 3-year clinical trial in participa…
- 421.
-
422.
Both the GLP-1 receptor agonist semaglutide and the novel dual GIP/GLP-1 receptor agonist tirzepatide have emerged as first-line therapeutic options for metabolic diseases. However, their real-world comparative safety profiles are difficult to interpret due to differential reporting composition in spontaneous reporting databases. This study compared their post-marketing adverse event (AE) reporting patterns and examined how reporter identity influences signal prominence. AE reports (May 2022-Jun…
-
423.
Obesity-related heart failure with preserved ejection fraction (HFpEF) is characterized by concentric remodeling, diastolic dysfunction, and systemic inflammation. Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial weight loss, but real-world echocardiographic evidence of cardiac reverse remodeling remains limited, particularly in prospective cohorts. We conducted a prospective, single-center, longitudinal observational cohort study of 50 adults with obesity-related HFpEF (LVEF…
-
424.
To characterise postmarketing safety signals and medication-use risks associated with GLP-1 receptor agonists and the GIP/GLP-1 co-agonist tirzepatide in diabetes and obesity care using an integrated pharmacovigilance, utilisation-context, regulatory, and external-consistency framework. FDA Adverse Event Reporting System (FAERS) data from 2021Q1 through 2026Q1 were processed using deleted-case exclusion, latest-case-version retention, and case-product deduplication with analysis at the GLP-1 pri…
- 425.
-
426.
Diabetic metabolic stress damages the cardiac microvasculature. We evaluated tirzepatide-associated cardiac and endothelial effects, including endpoint patterns after partial silencing of parkin RBR E3 ubiquitin protein ligase (PRKN) and lipidated microtubule-associated protein 1 light chain 3 beta (LC3B-II) accumulation during lysosomal blockade. Male C57BL/6J mice received a normal diet, a high-fat diet (HFD), or HFD/streptozotocin (STZ); HFD and HFD/STZ cohorts received tirzepatide or vehicle…
- 427.
- 428.
-
429.
Information on the effects of tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for obesity management in adults with obesity, remains limited in adolescents. To evaluate the efficacy and safety of once-weekly tirzepatide in adolescents with obesity or overweight with at least 1 obesity-related complication. This phase 3, randomized, double-blind, 72-week clinical trial was conducted at 31 medical research centers and ho…
- 430.
- 431.
-
432.
Tirzepatide reduces body weight and improves glycemic control, but real-world comparisons between individuals with obesity with and without type 2 diabetes (T2D) remain limited, as well as the potential influence on weight-loss response of baseline characteristics (especially sex and previous treatment exposure). We aimed to compare anthropometric and metabolic outcomes in these populations, as well as treatment persistence, discontinuation, and the influence of prior GLP-1 receptor agonist (GLP…
- 433.
-
434.
Weight loss with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is heterogeneous across individuals, yet the genetic causes of this variation are not fully known. We integrated exome sequencing data with electronic health records within the Helix Research Network (n = 351,818). Here, we show that, among 13,725 GLP-1RA-treated adults, carriers of rare damaging GLP1R variants lose less weight with semaglutide than matched non-carriers but achieve a near-normal tirzepatide response. Carriers…
- 435.
-
436.
Obesity or overweight occurs in 72% to 82% of individuals with psoriatic arthritis (PsA). Previous data revealed greater disease control with concomitant ixekizumab (IXE) and tirzepatide (TZP) versus IXE alone in adults with active PsA and obesity or overweight with at least one weight-related comorbidity at the week 36 primary end point. The objective of this report is to evaluate the effect of IXE+TZP versus IXE on psoriatic disease control and safety measures up to week 52. TOGETHER-PsA (Clin…
- 437.
-
438.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits remains unknown. The objective was to compare the effectiveness of semaglutide versus tirzepatide on the risk of major adverse cardiovascular events (MACE) in individuals with overwe…
-
439.
To characterize serum calcitonin dynamics during six months of tirzepatide therapy for obesity and explore whether early changes are associated with subsequent biochemical behavior. This prospective observational study enrolled 77 adults with obesity initiating tirzepatide. One participant diagnosed with medullary thyroid carcinoma at baseline was excluded, leaving 76 participants for longitudinal analysis. Serum calcitonin was assessed at baseline, 3 months, and 6 months. Longitudinal changes w…
-
440.
Incretin mimetics as obesity therapy induce substantial weight and fat loss but also decrease lean soft tissue mass, possibly impairing skeletal muscle function. Here, in this two-arm randomized controlled trial of adding resistance exercise (REx) to tirzepatide (T), 120 adults with overweight or obesity were treated with tirzepatide and randomized to thrice-weekly resistance exercise training or usual activities for 40 weeks. Tirzepatide was safe, and most participants tolerated up-titration to…
- 441.
-
442.
Tirzepatide (TZP) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated remarkable therapeutic efficacy for the treatment of type 2 diabetes and obesity. Despite its clinical importance, residue-specific information on its solution conformation remains limited due to its structural complexity, including noncanonical amino acids and a lipidated side chain. In this study, we performed a solution NMR investigation of…
-
443.
Glucagon-like peptide-1-based therapies improve metabolic outcomes, but longitudinal gut microbiome dynamics remain poorly characterized. We compared taxonomic and predicted functional microbiome responses to tirzepatide and semaglutide in Type 2 diabetes. This exploratory secondary analysis included 36 participants from a randomized controlled trial comparing tirzepatide, semaglutide and conventional treatment. Faecal samples were collected at five time points over 16 weeks and analyzed by 16S…
- 444.
-
445.
This pilot study evaluated changes in eating behavior, appetite, and dietary habits during semaglutide or tirzepatide treatment in adults with obesity. In this prospective observational study, 38 non-diabetic adults with obesity (mean age 56.1 ± 11.3 years; 73.7% female; BMI 32.7 ± 4.5 kg/m Mean body weight decreased by 7.2 ± 4.9 kg ( Over 3 months, incretin-based treatment was accompanied by weight loss and changes in self-reported eating behavior. The observational design, absence of a control…
-
446.
Obstructive sleep apnea (OSA) is a chronic respiratory disorder with nocturnal oxygen desaturation that is often associated with multisystemic sequelae such as hypertension, cardiovascular diseases, and increased morbidity and mortality. Obesity has been proposed as a modifiable risk factor; hence, the recent shift in focus to investigating anti-obesity medications for the management of OSA. Tirzepatide is the first U.S. FDA-approved pharmacotherapy for the treatment of moderate-to-severe OSA in…
Preprints (not yet peer-reviewed)
2-
447.
Glucagon-like peptide-1 (GLP-1) receptor agonists — including semaglutide (Ozempic®, Wegovy®) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro®, Zepbound®) — have transformed the management of type 2 diabetes, obesity, and cardiovascular disease. Yet a clinically significant and underappreciated challenge persists: profound inter-individual variability in both efficacy and tolerability. Some patients lose more than 20% of body weight; others less than 5%. Some experience debilitating nausea;…
-
448.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity treatment, yet weight-loss outcomes remain highly uneven in real-world care. Using a federated biomedical platform integrating 23 million de-identified U.S. patient records, we analyzed 135,349 individuals treated with GLP-1RAs and stratified them as “super responders” (>15% weight loss), “moderate responders” (5–15% weight loss), “minimal weight-loss group” (<5% weight loss), and “weight regainers”. super responders reve…
Case Reports
3-
449.
Glucagon-like peptide-1 (GLP-1) receptor agonists, including tirzepatide (Mounjaro), are widely used to manage type 2 diabetes mellitus (T2DM) and obesity. While gastrointestinal side effects are common, acute pancreatitis remains a rare but significant complication. Limited evidence exists on the risks associated with switching between GLP-1 agonists, emphasizing the need for clinical awareness. We present a 59-year-old male with T2DM, hyperlipidemia, and hypertension, who was recently transiti…
-
450.
The use of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide has markedly increased for the treatment of weight loss and management of diabetes mellitus. Gastrointestinal adverse effects of GLP-1/GIP agonist therapy, including nausea, vomiting, and constipation, are common. We report a case of colonic ischemia in a 62-year-old woman which developed in association with the use of tirzepatide for weight loss. This report highlig…
-
451.
We report a case of rhabdomyolysis triggered by initiation of tirzepatide, a novel dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The patient was a 68-year-old man with a medical history of type 2 diabetes mellitus (T2DM), dyslipidemia, and chronic kidney disease (CKD). After starting tirzepatide, he developed a significant elevation of creatine kinase (CK) and other muscle injury markers. These laboratory abnormalities rapidly r…
Curated sources on file
90- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.
- 40.
- 41.
- 42.
- 43.
- 44.
- 45.
- 46.
- 47.
- 48.
- 49.
- 50.
- 51.
- 52.
- 53.
- 54.
- 55.
- 56.
- 57.
- 58.
- 59.
- 60.
- 61.
- 62.
- 63.
- 64.
- 65.
- 66.
- 67.
- 68.
- 69.
- 70.
- 71.
- 72.
- 73.
- 74.
- 75.
- 76.
- 77.
- 78.
- 79.
- 80.
- 81.
- 82.
- 83.
- 84.
- 85.
- 86.
- 87.
- 88.
- 89.
- 90.